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Autoimmune diseases such as diabetes mellitus and multiple sclerosis are increasing 
today, but the mechanism behind these diseases remains largely unknown. 
Autoimmunity arise when the immune system of an individual start to attack its own 
organs and tissues. Immune cells go through a selection in central and peripheral organs 
where they are taught to be non-reactive to self structures, a process referred to as 
tolerance. In this thesis we have investigated the function of the autoimmune regulator 
(AIRE), a gene that is important for the establishment of tolerance. The autoimmune 
polyendocrine syndrome type 1 (APS I) is a rare severe autoimmune disease caused by 
a single mutation in the AIRE gene. These patients suffer from a range of endocrine and 
non-endocrine manifestations such as hypoparathyroidism and chronic mucocutaneous 
candida infections. Aire deficient mice have been created in order to enable the 
investigation on how tolerance is lost in APS I patients. These mice have revealed that 
AIRE is involved in the deletion of autoreactive T-lymphocytes in the thymus. AIRE is 
thought to induce the expression of tissue specific antigens (TSAs) that are presented to 
T-lymphocytes in the thymus. However, Aire deficient mice display a phenotype 
suggesting that additional tolerance mechanisms are affected. 
In the first paper presented in this thesis we show that AIRE is involved 
in the regulation of T-cell independent B cell responses and that Aire-/- mice display an 
increased activation of B cells. This increased activation was demonstrated to be due to 
increased serum levels of the B cell activating factor of the TNF-family (BAFF) in 
Aire-/- mice and APS I patients. The increased levels of BAFF were in turn found to be 
due to uninhibited signaling of IFN-γ through the STAT1-pathway in absence of AIRE. 
In the second paper it was demonstrated that AIRE is expressed by a specific dendritic 
cell in the marginal zone of the spleen. These dendritic cells were found to regulate the 
activation of T lymphocytes in germinal center reactions and displayed a phenotype 
suggesting their involvement in tolerance mechanisms. In the third project we 
demonstrated that the expression of Aire in the marginal zone dendritic cells was 
regulated by IFN-γ. Upon IFN-γ stimulation both the expression of Aire and the TSA 
insulin was quickly down-regulated while the expression of inflammatory cytokines 
was up-regulated. These data suggest that the marginal zone dendritic cells are able to 
participate in tolerance induction during steady state and switch to an immunogenic 
state during an immune response. In the last project we investigated the development of 
the marginal zone dendritic cell in the bone marrow and found that Aire is expressed in 
a precursor cell to the dendritic cell in the spleen. Further, it was found that in absence 
of AIRE the regulation of transcription factors important for the development of this 
particular dendritic cell subset was impaired.  
The findings from this thesis suggest that AIRE play an important 
function in the periphery and adds to the view that AIRE regulates both central and 
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1 INTRODUCTION 
Our immune system is made up of a dynamic network of cells, organs and tissues that 
work together to protect our body from pathogens. The term immunity derives from the 
Latin word immunis, meaning “exempt”, aiming at the phenomenon that an individual 
that has recovered from a disease is later on protected against the same disease. 
Observations of immunity were taken into practice by Edward Jenner and Louis 
Pasteur during the 18th and 19th century where they demonstrated that immunity could 
be deliberately achieved by the administration of a weakened pathogen, e.g. 
vaccination. However, immune responses can also lead to pathological conditions. 
Early in the 20th century Paul Ehrlich acknowledged that the immune system could go 
awry and direct its responses against the hosts own organs and tissues. He termed these 
events, which were later rephrased to autoimmunity, “Horror autotoxicus” (Kindt et al., 
2007).   
Today, autoimmune disorders affect 3-5% of a given population in 
western countries that may contribute to both psychosocial and economic burden for 
individuals as well as for the society (Jacobson et al., 1997). There is no treatment for 
autoimmune disease as one, instead the efforts lie on mending the isolated disease 
components.       
In order to prevent autoimmunity the immune system has evolved an 
educational system referred to as tolerance. During this education, immune cells go 
through several checkpoints in order to behave properly when encountering both 
friends and foes. The complex mechanisms of autoimmunity and tolerance can be 
better understood by studying patients with primary immunodeficiency where tolerance 
is affected, Autoimmune polyendocrine syndrome type I (APS I). In APS I the 
tolerance machinery is flawed by a single mutation in the autoimmune regulator gene 
(AIRE), leading to severe organ destruction. In order to study the function of the AIRE 
gene, mice that lack Aire have been engineered and revealed parts of the mechanisms 
behind AIREs function in tolerance.  
The aim of this thesis was to study the role of AIRE in peripheral 
tolerance mechanisms in order to investigate how immunity is maintained or broken.  
 
1.1 OVERVIEW OF THE IMMUNE SYSTEM   
The state of balanced immunity is maintained by two interconnected systems termed 
innate immunity and adaptive immunity. Innate immunity comprises the first line of 
defense and reacts rapidly but non-specifically to invading pathogens and the adaptive 
immunity makes up the specific and long term defense (Kindt et al., 2007).  
The innate immunity consists of physical barriers such as skin and 
mucosal membranes as well as a range of different cells. The phagocytic cells make up 
a very important part of the innate immune system by their ability to engulf pathogens 
and particles and thereby neutralize danger or envisage it to other components of the 
immune system. These cells include macrophages, neutrophils and dendritic cells 
(DCs) (Tauber, 2003). The innate immune system is further backed up by mast cells, 
basophils, eosinophils, natural killer (NK) cells and γδ T cells. The mast cells, 
basophils and eosinophils fight off pathogens, deal with wound healing and allergic 
reactions and asthma. The NK cells have cytotoxic activity and the ability to recognize 
a wide range of tumor cells and certain viruses and are, thus, very important in the 
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defense against these intruders. The γδ T cells, have a distinct feature from αβ T cells in 
the adaptive immunity, one of them is their ability to function as a phagocytic cell (Wu 
et al., 2009). Also, a variety of soluble factors contribute to the innate immunity such as 
lysozyme in mucous membranes that destroy the cell wall of bacteria, interferons and 
cytokines that are produced by infected cells in order to warn other cells, and the 
complement system that is a group of proteins that can destroy pathogens or mark them 
for destruction by other cells (Kindt et al., 2007).  
Due to their ability to phagocytose and present parts of pathogens on their 
cell surface, the dendritic cell is an important bridge between innate and adaptive 
immunity. DCs are a heterogeneous collection of migratory cells whose main function 
is to present antigens to T cells. The DCs will be reviewed in greater detail in section 
1.2.3. The adaptive immune system is made up of lymphocytes that mediate the 
specificity during an immune response and also contribute to the diversity and memory 
of the immune system. The lymphocytes are equipped with distinct antigen binding 
receptors and thus divide into two distinct categories, B lymphocytes and T-
lymphocytes (Kindt et al., 2007).  
The B lymphocytes, or B cells, bear an antigen receptor, or B cell 
receptor (BCR), that is a membrane bound antibody molecule that binds antigens (the 
active part of a molecule that induces an immune response). When a B cell encounter 
an antigen it responds by rapid division and is further maturated into plasma cells and 
memory B cells. The plasma cells produce antibodies as the one encountered by the 
antigen, but in a soluble form that can be secreted and engage the rest of the immune 
components. The memory B cells are long lived cells that will react quickly when 
encountering the same antigen a second time. In addition there are specialized B cell 
subsets residing in different organs, like the B-1 cells in the peritoneal cavities and the 
marginal zone B cells (MZBs), follicular B cells (FOBs). Activated B cells that have 
come in contact with T-cells in spleen and lymph nodes will enter germinal centers 
(GCs) to enhance their antigen specificity and are then referred to as germinal center B 
cells (GCBs). The B cell subsets are best characterized in mice, but the knowledge of 
these cells is emerging in humans (Allman and Pillai, 2008; Martin and Kearney, 2002; 
Shlomchik and Weisel, 2012).    
Conventional T cells, or αβ T cells, bear a T cell receptor (TCR) that 
typically only recognizes antigens that are bound to major histocompatibility complex 
(MHC) molecules, for example MHC II expressed on dendritic cells. There are two 
major subpopulations of these T cells, T helper cells that express CD4 on their cell 
surface and cytotoxic T cells that express CD8. The T helper cells assist other immune 
cells in different immunological functions as well as activating the cytotoxic T cells 
which main function is to destroy infected cells and tumor cells (Kindt et al., 2007). 
When activated, the T helper cells can divide into one of several different subtypes that 
secrete different sets of cytokines depending on the type and location of activation. The 
Th1 cells secrete IFN-γ and IL-2 and activate cytotoxic T cells. Th2 cells secrete, 
among others, IL-4 and IL-10 and mainly aids in the activation of B cells (Murphy and 
Reiner, 2002). Th17 cells secrete IL-17, important in inflammation and tissue injury 
(Harrington et al., 2005). Finally, T follicular helper (Tfh) cells are activated T cells 
that have come in contact with a B cell and make up a crucial part of the germinal 
center reactions in the spleen and lymph nodes together with GCBs (Crotty, 2011). 
Apart from the cytotoxic T cells and the T helper cells there are also T regulatory cells 
(Tregs) that are important for immunological tolerance, two subsets of long lived 
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memory T cells and NKT cells that recognize antigens presented by the molecule CD1d 
instead of MHC that, as the innate NK cells, can kill target cells (Rossjohn et al., 2012; 
Sakaguchi et al., 2008; Sallusto et al., 1999).       
 
 
1.2 TOLERANCE AND AUTOIMMUNITY 
As reviewed above, our immune system has evolved with the purpose of fighting off 
invading pathogens. However, equally important is the ability to distinguish self from 
non-self, an important mechanism referred to as tolerance. The breakdown, or loss of 
tolerance to self, results in responses against self-components that may lead to 
autoimmune disease. During their development, B and T lymphocytes undergo 
educational processes in primary lymphoid organs where they are taught to distinguish 
between self and non-self. These mechanisms are together referred to as central 
tolerance. Although the central tolerance machinery makes an excellent work of 
keeping the lymphocytes in check, nobody’s perfect, and the immune system has 
therefore developed an artillery of safety mechanisms outside of the primary lymphoid 
organs, termed peripheral tolerance.  
 
1.2.1 T-lymphocytes 
T cell precursors originate in the bone marrow, but the development into the different T 
cell subsets, CD4+ T cells and CD8+ T cells, occur in specialized structures in the 
thymus that is populated by antigen presenting cells; cortical thymic epithelial cells 
(cTECs), medullary thymic epithelial cells (mTECs) and DCs (Capalbo et al., 2012; 
Holländer et al., 1995). The T cell progenitors, thymocytes, enter the cortex of the 
thymus as CD4/CD8 double negative (DN) cells where they make a commitment to the 
αβ T-cell lineage. During this process the DN thymocytes first rearrange their TCR β 
chain, through a series of steps involving induction of recombination activating genes 
(RAG) and the expression of a pre-TCR α chain. Once a functional TCR β chain 
complex is arranged, the RAG, pre-TCR α chain, and CD25 is downregulated, resulting 
in a burst of cell proliferation and subsequent upregulation of CD8 and CD4. The 
double positive cells (DP) then finally rearrange their TCR α chain and display a fully 
assembled TCR complex ready for positive selection (Anderson et al., 2006; von 
Boehmer and Fehling, 1997). 
During positive selection the DP thymocytes are presented with self-
MHC molecules on the surface of cTECs. In order to increase the chances of binding to 
a presented MHC complex, the DP thymocytes can extrapolate the rearrangement of 
their TCR α chain during a process referred to as receptor editing (Capalbo et al., 
2012).  Those DP thymocytes bearing TCRs that are able to bind to MHC with 
adequate affinity will receive rescue signals through the TCR and differentiate into 
CD4+CD8- and CD4-CD8+ single positive (SP) thymocytes. The preference of the 
thymocytes to bind to either MHC I or MHC II molecules will determine whether it 
will downregulate the CD4 or CD8 co-receptor , respectively. DP thymocytes with 
TCRs unable to bind to self-MHC molecules will not receive a rescue signal are 
programmed to undergo apoptosis. Approximately 95% of all DP thymocytes are 
eliminated at this stage (Jameson et al., 1995; Kisielow et al., 1988; Zinkernagel et al., 
1978).  
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Thymocytes that have gone through the process of positive selection will 
be directed to the medulla of the thymus to undergo negative selection. During this 
selection, thymocytes are checked for unresponsiveness against self-peptides so that 
potentially autoreactive T cells can be cleared off before entering the circulation 
(Palmer, 2003). This process is dependent on the display of a wide range of tissue-
specific antigens (TSAs) that the cells may encounter in the periphery. These TSAs are 
expressed by mTECs along with more than 1000 other promiscuous genes (Derbinski 
et al., 2005). However, only 1-2% of the mTECs express a particular antigen and one 
mTEC only expresses a few antigens. Thus, the mTECs are aided by DCs that have the 
ability to scan a huge amount of mTECs for a short period of time. The DCs are also 
thought to take up self-peptides through apoptotic mTECs or picking them up in the 
periphery before migrating to the thymus (Derbinski et al., 2008; Koble and Kyewski, 
2009). Thymocytes that bind with high affinity to self-antigens presented by mTECs or 
DCs will be subjected for clonal deletion by apoptosis (Punt et al., 1994). Thus, both 
the mTECs and the DCs are equipped with a range of co-stimulatory molecules, such as 
CD40, CD80 and CD86, that can mediate activation of the Fas signaling pathway 
leading to apoptosis (Capalbo et al., 2012; Foy et al., 1995). Some of the thymocytes 
that binds to self-antigen complexes with high affinity are thought to develop into 
CD4+CD25+ regulatory T cells (Treg) expressing FOXP3 (Schubert et al., 2001). The 
Tregs have been shown to play an important role in maintenance of peripheral 
tolerance, but how these cells escape negative selection is more elusive. However, the 
induction of Treg differentiation is thought to be mediated by DCs activated by thymic 
stromal lymphopoietin (TSLP) in the Hassal’s corpuscles (Watanabe et al., 2005).  
Thymic deletion of autoreactive T-cells is efficient, although, T-cells with 
low affinity for self-antigens are usually found in the periphery. (Bouneaud et al., 
2000). Thus, several mechanisms exist for preventing self-reactive T-cells to become 
activated in peripheral lymphoid organs. These include ignorance, induction of anergy, 
deletion by apoptosis, and the suppressive actions of Tregs (Abbas et al., 2004). 
Ignorance is the simplest of all mechanisms, which means that T cells in the periphery 
ignore self-antigens either because of to low levels of antigen or no accessibility of the 
antigen (Walker and Abbas, 2002). Anergy is induced when T-lymphocytes are 
activated via their TCR, or perhaps also through other surface receptors, by a certain set 
of co-stimulatory signals that results in functionally unresponsive lymphocytes. Two of 
these co-stimulatory signals are thought to be the cytotoxic T-lymphocyte associated 
antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) (Freeman et al., 2000; Perez 
et al., 1997). Tregs exert their function as suppressors of autoreactive T cells by the 
release of inhibitory cytokines such as IL-10 and TGFβ (Groux et al., 1997; Shevach, 
2009). Tregs have been shown to be indispensable for the maintenance of peripheral 
tolerance, demonstrated by the fact that absence of Tregs in both mice and humans 
leads to severe autoimmune disease. Further, transfer of Tregs from healthy mice does 
prevent disease in autoimmune mice models (Vignali et al., 2008).  
 
1.2.2 B-lymphocytes  
The mechanisms of tolerance during B cell development in the bone marrow resemble 
those for the T cells in the thymus. One major difference, though, is the fact that B cells 
are not yet fully mature lymphocytes when entering the periphery. This is possibly a  
consequence of a less promiscuous antigen expression in the bone marrow compared to 
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the thymus (Wardemann and Nussenzweig, 2007). B cell tolerance mechanisms seem 
to be similar in mice and humans (Ghia et al., 1998). 
B cells develop from hematopoietic stem cells and go through three 
sequential recombination steps to become immature B cells with a functional BCR. At 
the pro-B cell stage expression of RAG genes induce rearrangement of 
immunoglobulin (Ig) heavy chain gene segments (Pieper et al., 2013). At the second 
step, the pre-B cells stage, a surrogate light chain is rearranged, resulting in a pre-BCR 
complex (Melchers, 2005). The pre-BCR has two important tasks; the first is to 
shutdown the RAG genes in order to stop heavy chain rearrangement, referred to as 
allelic exclusion, and the second is to initiate light chain rearrangement (ten Boekel et 
al., 1998). At the last step, assembly of the heavy and light chains results in the 
expression of an IgM on the cell surface of an immature B cell. The rearrangement of 
the heavy and light chains of the BCR creates a diverse repertoire of antibodies capable 
of recognizing more than 5 x 1013 different antigens (Pieper et al., 2013). However, the 
advantages of recognizing such a diverse range of pathogens might be overshadowed 
by the fact that some of these randomly generated antibodies may react to self-antigens. 
To avoid this, the developing B cells are checked for autoreactivity at two different 
check points (Meffre et al., 2004; Wardemann et al., 2003). One of these checkpoints 
occurs at the early immature B cell stage in the bone marrow (before appearance of 
surface IgM) where the BCR plays a crucial role. B cells that receive a strong signal 
from the newly formed BCR will be subjected to deletion by apoptosis. B cells that 
receive an intermediate signal through their BCR will be given a second chance to 
display a non-self reactive BCR through the process of receptor editing. During this 
process, the B cell will further rearrange the light chain genes until a non-self-reactive 
BCR is displayed. B cells that fail to do this will be deleted (Gay et al., 1993). Also, 
self reactive B cells can be rendered non-responsive and leave the bone marrow in a 
state of anergy (Goodnow et al., 1988). However, anergy may only account for the 
removal of a few autoreactive B cell clones, whereas receptor editing applies to 20-50% 
of all developing B cells (Casellas et al., 2001). The importance of the BCR in the 
prevention of autoreactive B cells has been demonstrated in mice and humans. For 
example, a polymorphism in a specific allele in humans, PTPN22, leads to decreased 
BCR signaling that is thought to be the reason for the entering of autoreactive immature 
B cells in the periphery in systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA) (Meffre, 2011).  
IgM expressing immature B cells leaving the bone marrow are regulated 
by a second tolerance checkpoint in the periphery. The mechanism of this checkpoint is 
less understood compared to the bone marrow checkpoint, however, the immature B 
cells are thought to go through two transitional stages on the way to a mature naïve B 
cell (Wardemann and Nussenzweig, 2007). The survival of the transitional B cells is 
dependent on the expression of a functional BCR and signals from the B cell activating 
factor of the TNF family (BAFF), a cytokine secreted by DCs and stromal cells 
(Schneider et al., 1999). BAFF promotes the survival of transitional and naïve B cells 
through a BAFF receptor and two additional receptors depending on the subtype of 
naïve B cell (Gross et al., 2000). Thus, a defect in the expression or secretion of BAFF 
affects the regulation of all B cells. For example, BAFF deficient mice display a severe 
reduction in B cell numbers and halted development at the second transitional stage 
(Batten et al., 2000). Conversely, overexpression of BAFF alters the development of 
transitional B cells leading to increased survival of autoreactive B cells (Mackay et al., 
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1999). In humans, increased levels of serum BAFF is usually seen in autoimmune 
diseases as Sjögren’s syndrome and SLE (Tangye et al., 2006). The importance of 
Tregs in the peripheral tolerance checkpoint has recently been demonstrated in patients 
lacking this celltype, which display a severe phenotype including autoreactive B cells 
(Kinnunen et al., 2013). 
The naïve mature B cells are further differentiated into one of three 
different subtypes depending on its homing site. In mice, marginal zone B cells (MZB) 
are non-circulating cells in the marginal zone of the spleen that participate in the early 
immune response against blood-borne antigens in a T cell-independent manner (Lopes-
Carvalho and Kearney, 2004). Human MZB cells are recirculating and express IgM 
carrying somatic hypermutations (SHMs) that is thought to develop independently of 
clonal expansion in germinal centers. Apart from this, human and mouse MZB cells 
seem to share similar functions (Pieper et al., 2013). MZB cells need low levels of 
antigen for activation, and the findings that autoreactive MZB cells are spontaneously 
activated without T cell help implicate that these cells are involved in autoimmune 
responses (Pillai et al., 2005, Mandik-Nayak et al., 2006). Furthermore, MZB cells also 
participate in T-cell dependent responses by capturing antigens and presenting them to 
follicular B cell (FOB). FOBs migrate through the blood, lymph and the follicles of the 
spleen where they take part in T-cell dependent responses (Allman and Pillai, 2008). T-
cell dependent responses results in the differentiation of plasma cells and memory B 
cells. Some plasma cells can differentiate in the extrafollicular areas of the spleen 
without further T cell help and quickly secrete antibodies (MacLennan et al., 2003). 
Memory B cells, as well as plasma cells, are generated in germinal centers (GCs) where 
activated B cells, GCB cells, go through SHMs to further diversify their antibody 
repertoire. The GCB cells are presented with cognate antigen by follicular dendritic 
cells in the light zone of the GC and migrate to the dark zone where activation induced 
cytidine deaminase (AID) initiate SHM. The SHMs will either result in an increased 
BCR affinity leading to the formation of memory B cells or plasma cells, removal of 
non-functional BCRs by apoptosis or a change in the antibody specificity of the BCR, 
leading to an autoreactive B cell (MacLennan, 1994; Wardemann and Nussenzweig, 
2007). Competition for antigen together with stable interactions with Tfh cells are 
thought to favor the assembly of high affinity BCRs (Allen et al., 2007). Tfh cells are 
equipped with several cytokines and several co-stimulatory molecules such as IL-21, 
PD-1 and the inducible co-stimulator (ICOS) respectively, making them important for 
the activation and survival of GCB cells. Conversely the GCB cells are important for 
Tfh cells and together they facilitate the survival of one another (Crotty, 2011). The 
choice between extrafollicular antibody responses and GC selection seems to be 
influenced by the signaling from the BCR upon initial antigen crosslinking. BCRs with 
high affinity are more frequently found in the extrafollicular areas while low affinity 
BCRs go into germinal centers (Wardemann and Nussenzweig, 2007). Apart from 
proper BCR signaling, BAFF secretion, Tregs and AID, MHC II expression and CD40-
CD40L interactions also seems to play a role for the prevention of autoreactive B cells 
in the periphery (Meffre, 2011).   
 
1.2.3 Dendritic cells 
Dendritic cells do not express antigen specific receptors such as the TCR and BCR and 
therefore, do not go through the self/non self education as the T- and B-lymphocytes 
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do. However, the dendritic cells play a major role in governing both the education of 
lymphocytes and their action during an autoimmune response. Since the DCs are 
professional antigen presenters, and the main producers of cytokines in the immune 
system, they are responsible for the initiation, direction and strength of an immune 
response. Although the DCs were discovered 40 years ago the research on DCs in 
tolerance and autoimmune diseases has been standing in the shadow of the 
lymphocytes (Steinman and Cohn, 1973). However, emerging data in the recent years 
have shown the importance of DCs in the immune response and appreciation of the role 
of different subtypes. 
One obstacle in DC research has been the fact that they are a much more 
heterogeneous group of cells then earlier thought and the identifying markers differ 
greatly between mice and human DCs. Common for both mice and human DCs are, 
though, the division between non-lymphoid tissue migratory and lymphoid tissue 
resident DCs and plasmacytoid DCs (pDCs) (Merad and Manz, 2009). The main 
function of the resident lymphoid DCs is to maintain self-tolerance and induction of 
specific immune responses, whereas the pDCs are important producers of cytokines in 
response to viral infections (Banchereau and Steinman, 1998; Liu, 2005; Steinman et 
al., 2003).  
In mice, the non-lymphoid tissue DCs includes those that express CD103 
(e-cadherin ligand), those that do not express CD103 and the langerin expressing DCs 
referred to as Langerhans cells (Merad and Manz, 2009). The lymphoid tissue resident 
DCs are made up of two major subpopulations both of them mainly situated in the 
spleen. One population is located to the T cell zone of the spleen and expresses CD8a 
and the C-type lectin DEC205 and the other population resides in the marginal zone 
and red pulp and expresses the surface marker 33D1 and CD4 (Dudziak et al., 2007). 
The CD8a+DEC205+ DCs have been shown to be specialized for MHC I restricted 
cross presentation (den Haan et al., 2000), whereas the 33D1+CD4+ DCs primarily 
elicit MHC II restricted T cell responses (Dudziak et al., 2007). There is also the 
presence of a double negative DCs population (CD8a-CD4- DCs) in the spleen, but it is 
usually more prominent in mesenteric lymph nodes. The CD8a+DEC205+ is the only 
DC population of these three to be found in the thymus (Shortman and Liu, 2002). 
Mouse pDCs express low levels of CD11c and high levels of PDCA-1 and the lectin 
siglec-H. The pDCs are widely distributed throughout the body, but are more 
frequently accumulated in the liver (Merad and Manz, 2009). An overview of the 
murine subtypes of DCs in primary and secondary lymphoid organs, blood and skin is 
depicted in Figure 1.   
Accessibility to mouse lymphoid organs and tissues compared to humans 
has meant fewer studies on human DC subsets. Human DCs have therefore been 
mainly studied in blood and it has been difficult to assess whether differences in the 
expression of surface markers reflect subpopulations of DCs or simply differences in 
maturation (Ueno et al., 2011). However, there are three distinct DC populations in 
human blood. The major population of the lin-HLA-DR+CD11c+ DCs expresses the 
molecule CD1c (BDCA-1) and express a variety of Toll-like receptors (TLRs). A 
second, smaller population, expresses CD141 (BDCA-3) and the c-type lectin 
CLEC9A. The CD141+ DCs have been given much attention lately since they have 
been suggested to correspond to the mouse CD8a+ DC population (Jongbloed et al., 
2010; Poulin et al., 2010). The human DCs do not express CD8α, the correlation has 
instead been made through the shared expression of CLEC9A, NECL2 and XCR1  
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Figure 1. A schematic overview of the different murine subtypes of dendritic cells in primary 
lymphoid organs, secondary lymphoid organs, skin and blood during steady state. Illustration 
courtesy of Dr. M Winerdal. 
(Bachem et al., 2010; Crozat et al., 2010). The third human DC population in blood is 
the pDCs that is distinguished by the expression of BDCA-2 and ILT7 and is thought to 
have the same function as the mouse counterpart.  
Interestingly, there are two subtypes of pDCs in humans compared to 
mice who only have one. These subtypes are distinguished by the differential 
expression of CD2 and represent distinct transcription profiles. The CD2high subset is 
thought to induce a more potent allogeneic T cell proliferation than the CD2low subset 
(Matsui et al., 2009). Another site of DC characterization in humans has been the skin 
and here one can also find three distinct subtypes of DCs. In the epidermis of the skin 
reside only the Langerhans cells (LCs) expressing langerin and DCIR while the dermis 
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contains two subsets of DCs. The dermal DCs are CD1a+ DCs and CD14+ DCs. The 
CD14+ DCs have been shown to be able to induce naïve CD4+ T cells to differentiate 
into T follicular helper- like cells (Ueno et al., 2011; Valladeau and Saeland, 2005).   
Taken together, all these reports demonstrate that dendritic cells are a 
heterogeneous population of migrating cells, which have strong influences on tolerance 
induction and activation of regulatory cells depending on the location, activation status 
and type of DC. DCs that maintain tolerance in the immune system are collectively 
named tolerogenic DCs and any imbalance in the homeostasis of these cells could 
consequently lead to the development of autoimmune disease. An example where 
altered migration and maturation of DCs leads to autoimmune disease have been 
demonstrated in multiple sclerosis patients where increased percentage of DCs express 
co-stimulatory molecules such as CD80 and CD40 at the same time as another DC 
subset, expressing inhibitory molecule PD-L1, is reduced (Karni et al., 2006). Another 
example is seen in rheumatoid arthritis where an increased and selective recruitment of 
DC precursors expressing inflammatory chemokines is observed in the joints of 
patients (Santiago-Schwarz, 2004). Several research groups have linked the 
hyperactivation of T cells typically seen in patients with SLE to alterations in DCs, for 
example a down-regulation of the differentiation marker CD83 compared to healthy 
controls (Ding et al., 2006).  
Furthermore, it has become increasingly apparent that the production of 
cytokines from DCs is an important step in either mediating tolerance or causing 
autoimmunity. The most prominent example of cytokine-mediated induction of 
tolerance by DCs is the induction of Tregs. Although natural Tregs are thought to be 
induced through antigen presentation by DCs without activation signals, the induction 
of adaptive Tregs in the periphery is thought to be dependent on IL-10 and TGF-β from 
DCs (Wakkach et al., 2003; Yamazaki et al., 2008). Interestingly, activation of Tregs 
by DCs has shown to induce the production of IL-10 also by the Treg itself, thus 
indicating the presence of a Treg-DC homeostasis mechanism (Maldonado and von 
Andrian, 2010). Examples of DCs causing autoimmunity are the overproduction of 
TNFα in psoriasis and RA, and increased levels of type I interferons in Sjögrens 
syndrome and SLE thought to originate from pDCs (Steinman and Banchereau, 2007). 
Furthermore, IL-12 produced mainly by activated cDCs play a crucial role in the 
differentiation of Th1 cells and blocking of this cytokine has been found to ameliorate 
disease in Crohn´s patients (Mannon et al., 2004). 
 It has long been suggested that only immature DCs are involved in 
tolerance induction and that mature DCs instead have immunogenic properties 
(Shortman and Liu, 2002). Recent reports do, however, point at a mechanism where 
both immature, semi mature or mature quiescent DCs may induce tolerance by 
presenting self-antigens, killing T cells, or inducing Tregs. If these DCs then are 
subjected to an activation triggering signal, like a viral infection, they will shift to an 
immunogenic state providing T cells with MHC and co-stimulatory molecules leading 
to their activation (Blanco et al., 2008; Torres-Aguilar et al., 2010). Specific markers 
for tolerogenic DCs have not yet been identified, however, one candidate is the 
inhibitory immunoglobulin like transcription (ILT) receptors found on some tolerazing 
DCs (Manavalan et al., 2003). The potential capacity of tolerogenic DCs to prevent and 
ameliorate autoimmune disease have led to emerging studies of inducing tolerogenic 
DCs for the use in clinical practice both as ex vivo generated DC vaccines and DC 
targeting. Some of these studies have been successful in generating immune tolerance 
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in both animal models and human patients. However, due to the diversity and the 
plastic nature of DCs there are still a lot of obstacles to overcome before DC-therapy 
can be used as a safe and validated treatment. Routes and time points of administration, 
the origin and subtype of DC and the type of antigen chosen to be presented are 
examples of factors that need to be carefully considered (Gross and Wiendl, 2013; 
Ueno et al., 2011).   
 
1.3 AUTOIMMUNE DISEASE  
Despite the machinery of preventive mechanisms against auto reactivity in both 
primary and secondary organs, individuals still suffer from autoimmune disease. It is 
estimated that approximately 5% of the population in western countries suffers from 
autoimmune disease, where autoimmunity in thyroid organs, the bowel and stomach 
accounts for the highest prevalence (Jacobson et al., 1997; Marrack et al., 2001). The 
definition of autoimmune disease was re-postulated by Rose and Bona in 1993 to 
include 3 categories: 1) direct evidence that a disease can be reproduced in a healthy 
human or animal by the transfer of autoantibodies or antigen specific T cells, 2) indirect 
evidence that an autoimmune disease can be induced by immunization with target 
autoantigen or by administration of isolated autoantibodies from an autoimmune animal 
model or 3) circumstantial indirect evidence of disease where autoantibodies are 
isolated from the major target tissue of the individuals affected by disease (Rose and 
Bona, 1993; Witebsky et al., 1957).  
Clinically, autoimmune diseases are classically divided into two major 
categories: organ specific and non-organ specific or systemic autoimmune disease. 
Organ specific disease is either caused by direct cellular damage or by stimulating or 
blocking autoantibodies (Kindt et al., 2007). An example of autoimmune disease 
caused by cellular damage is insulin dependent diabetes mellitus (IDDM) where an 
autoimmune attack directed against the β-cells of the pancreas leads to decreased levels 
of insulin and consequently to increased blood glucose levels (Lernmark and Larsson, 
2013). In Myasthenia gravis, on the other hand, the autoimmune disease is caused by 
antibodies that block the acetylcholine receptors on muscles, hindering the binding of 
acetylcholine consequently leading to weakened skeletal muscles. Examples of 
systemic autoimmune disease are SLE and RA where the autoimmune response is 
affecting a wide range of organs and typically several target antigens and most 
commonly is a result of hyperactive B and T cells (Kindt et al., 2007).  
 
1.3.1 Etiology of autoimmune disease 
The understanding of autoimmune diseases has emerged over the past century. 
However, the underlying mechanism resulting in immune destruction still confuses 
researchers today. Several mechanisms for the initiation and maintenance of 
autoimmune disease have been proposed and thus, the appreciation that several factors 
may lead to disease progression (Davidson and Diamond, 2001; Marrack et al., 2001).  
Multiple genetic factors accounts for the susceptibility in a majority of 
autoimmune diseases. Typically, clustering of several diseases and co-association of 
autoimmune disease in relatives is often seen. In addition, the concordance rate of 
autoimmune disease is higher in monozygotic twins than in dizygotic twins (Klein and 
Sato, 2000). Most autoimmune diseases are polygenic i.e. several susceptibility genes 
contribute synergistically to the development of disease.  The majority of autoimmune 
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diseases are linked to the human leukocyte antigens (HLA). The strongest association is 
seen with the major histocompatibility complex class II (MHC II) and certain 
autoimmune diseases where a specific self-antigen is attacked, as is seen in RA and 
IDDM. Interestingly, it is also known that some HLA alleles can protect from disease 
even if other susceptibility genes are present (Davidson and Diamond, 2001). There are 
also susceptibility genes that act on immune cells directly and thus, control the overall 
immune response of an individual. An example of this is seen in a polymorphism of the 
CTLA-4 gene, which is important for down regulation of T cell activation, often 
associated with IDDM and celiac disease (Holopainen et al., 1999; Marrack et al., 
2001).  
A few autoimmune diseases are, however, caused by mutations in one 
single gene, nevertheless, the disease etiology can still be complex. The best 
characterized monogenic autoimmune diseases are immune-dysregulation 
polyendocrinopathy enteropathy X-linked (IPEX), autoimmune lymphoproliferative 
syndrome (ALPS) and autoimmune polyendocrine syndrome type I (APS I) (Davidson 
and Diamond, 2001). IPEX is caused by mutations in the FOXP3 gene, which is 
responsible for the development of regulatory T cells. Patients with IPEX develop 
severe and lethal symptoms very short after birth, most typically diabetes mellitus, 
severe diarrhea and hemolytic anemia (Bennett et al., 2001). ALPS is a autosomal 
dominant inherited disease where defects in the Fas protein or its receptor causes 
hyperproliferation of lymphocytes due to inability to induce apoptosis (Rieux-Laucat et 
al., 1995). APS I is an autosomal recessive disorder due to mutations in the AIRE gene 
which will be discussed in more detail in chapter 1.4.  
It is apparent that also in these monogenic autoimmune diseases patients 
with the same disease display differences in disease spectrum and severity. For 
example it is not uncommon that siblings carrying the same mutation have different 
clinical features (Davidson and Diamond, 2001; Marrack et al., 2001). Also, the 
autoimmune disease concordance rate between monozygotic twins is far from fulfilled 
(Salvetti et al., 2000). Thus, other genes and non-genetic factors may also affect the 
etiology of autoimmune diseases.  
The initiation of several autoimmune diseases has been connected to the 
presence of infectious agents such as bacterial and viral products. This may occur 
through several different mechanisms such as molecular mimicry and the release of 
sequestered antigens. Molecular mimicry describes the situation where an epitope of a 
microorganism resembles that of an antigen in a host leading to cross-reactivity. For 
example, cross-reactivity between streptococcal and cardiac proteins causes rheumatic 
fever and cross-reactivity between a peptide from the autoantigen glutamic acid 
decarboxylase 65 (GAD65) and the protein 2C of coxsackie B virus has been suggested 
as the mechanism resulting in the development of IDDM (Guilherme et al., 1995; 
Kukreja and Maclaren, 2000). Antigens that are normally protected from immune 
recognition at immune privileged locations such as the eye can be released during 
organ destruction and encounter a T cell for the first time leading to re-stimulation and 
a further exaggerated autoimmune response. This spreading of sequestered antigens 
may account for the cause of autoimmunity in some diseases (Kindt et al., 2007).  
Theories that chance plays a role in the induction of autoimmune diseases 
have been proposed. Thus, stochastic events during T and B cell receptor 
recombination, somatic mutations and the degree of cell death may account for the 
differences of disease spectrum seen between monozygotic twins with the same 
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autoimmune defect (Germain, 2001; Mackay, 2005). Other non-genetic factors that 
may lead to autoimmunity are diseases or stress leading to lymphopenia, meaning that 
the number of lymphocytes in an individual is reduced. In order to balance this, the 
immune system turns on a homeostatic proliferation of cells which can lead to a 
skewed lymphocyte repertoire, for example favoring the development of autoreactive T 
cells (Ernst et al., 1999; Surh and Sprent, 2002).      
Disease susceptibility between sexes differs greatly in several 
autoimmune diseases. The incidence of the rheumatic systemic diseases RA and SLE 
are for example about 70-90% higher in women than in men. Both genetically and 
physiological differences are thought to account for this predisposition. For example, in 
SLE, several X-linked genes such as CD40L and (IRAK1) are thought to be over-
expressed in women due to incomplete X inactivation (Tiniakou et al., 2013). Also, 
female hormones may influence disease susceptibility, since estrogen support the 
survival of auto reactive T cell clones (Pennell et al., 2012). 
Apart from describing the concept of tolerance as the immune systems 
recognition of self versus non-self, another model of unresponsiveness is the danger 
model. This model proposes that antigen presenting cells are activated only by danger 
signals from injured cells and thus need to be able to distinguish what is harmful from 
what is not (Matzinger, 1994; Matzinger, 2002). The danger model would subsequently 
better explain some of the mechanisms of the autoimmune disease etiologies reviewed 
in this chapter.   
  
1.3.2 Autoantigens and autoantibodies 
The autoantigens recognized by immune cells leading to the destruction of tissues and 
organs are only known for a small fraction of all autoimmune diseases. One reason for 
this is suggested to be due to changes in T cell and B cell responses as disease 
progresses in such a way that the response is focused on another autoantigen than the 
initial target autoantigen. This phenomenon is referred to as epitope spreading 
(Davidson and Diamond, 2001). Also, the autoimmune attack does not always occur at 
all of the sites where the autoantigen is found and it is now evident that both 
lymphocytes and autoantibodies contribute to devastation (Lernmark A, 2001).    
Among the autoimmune diseases where the autoantigen have been 
identified and correlated with disease are those at the neuro-muscular junction, for 
example the voltage-gated calcium channels in acquired neuromyotonia or Isaac’s 
disease. Desmoglein I have been identified in pemphigus vulgaris (PV) and the TSH 
receptor have been found in Graves’ disease. In models of these diseases, the antibodies 
to these autoantigens will cause disease when transferred to an animal model 
(Steinman, 1995). Other well characterized autoantigens with a strong correlation to 
disease is the glutamic acid decarboxylase GAD in IDDM, myelin basic protein (MBP) 
in multiple sclerosis (MS) and fibrinogen in RA (Hayter and Cook, 2012; Lernmark A, 
2001).  
Autoantibodies are the immunoglobulins produced in response to a given 
autoantigen. Despite the fact that autoantibodies are directed against self, they class 
switch from IgM to IgG, show high specificity and undergo affinity maturation just like 
normal antibodies (Plotz, 2003). Both activated autoreactive T cells and the 
autoantibodies themselves contribute to tissue destruction during an autoimmune 
attack. For example autoantibodies in Grave’s disease interfere with the physiology of 
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thyroid cells and the autoantibodies against desmoglein I t in PV induce release of 
proteases leading to the blister formation that is characteristic for the disease (Davidson 
and Diamond, 2001).  
Despite the difficulties of pinpointing the right autoantibodies to the right 
autoantigen, and the corresponding disease, autoantibodies have proved to be a 
valuable tool for the characterization and prediction of some autoimmune diseases. 
Autoantibodies against organ specific diseases such as IDDM and thyroiditis can, for 
example, be detected long before the actual tissue destruction has started. Also, there 
are some diseases, such as athropic gastritis, which can have several causes but the 
detection of autoantibodies against H/K ATPase determine the cause as autoimmune 
gastritis (Lernmark and Larsson, 2013; Leslie et al., 2001).  
When it comes to treatment or prevention of autoimmunity a lot of focus 
in the recent years has been on the use of autoantigens. Most of the efforts have been 
directed at Non-obese diabetic (NOD) mice and patients with IDDM where 
autoantigens are administered with the purpose of redirecting the immune response into 
a protective one and thus maintain β-cell function (Culina et al., 2013; Skyler, 2013). 
Although, these treatments have not had much success so far, perhaps a deeper 
knowledge of the actual pathogenesis of autoantigens and autoantibodies are still 
needed in order to be able to reinstate tolerance.  
 
1.3.3 Autoimmune polyendocrine syndromes 
Autoimmune polyendocrine syndromes are a collection of rare autoimmune diseases 
with mainly endocrine manifestations. The syndromes are divided into four different 
groups (APS I-IV) that tend to associate with each other and sometimes also with other 
autoimmune diseases (Eisenbarth, 2004; Neufeld et al., 1981).  
APS I is the only monogenic disorder of the four and is characterized by 
the presence of hypoparathyroidism, adrenocortical insufficiency (Addison’s disease) 
and chronic mucocutaneous candidiasis (CMC). APS I will be described further in 
chapter 1.4.  
APS II, also called Schmidt’s syndrome, is more common than the other 
syndromes and probably the most diverse. APS II is a complex genetic disorder 
showing strong association with HLA, in particular to a heterozygous HLA-DR3/HLA-
DR4 locus. The same locus is also strongly associated with Addison’s disease which is 
the most frequent disease component in APS II (Husebye and Anderson, 2010). Apart 
from Addison’s disease APS II is typically characterized by the presence of 
autoimmune thyroid disease and/or IDDM, but also minor autoimmune diseases such 
as vitiligo and alopecia may be present. APS II is typically more frequent in women 
and usually has an insidious onset, where manifestations typically present in adult life 
(Eisenbarth, 2004).  
APS III is characterized by the presence of autoimmune thyroiditis and at 
least one other autoimmune disease without the presence of Addison’s disease. The 
inheritance of APS III is currently unknown. Individuals with a combination of 
autoimmune diseases, apart from the ones found in APS I-III, belong to the very rare 
group, APS IV. The combinations can for example be the presence of IDDM together 
with hypogonidism, chronic gastritis and coeliac disease (Betterle and Zanchetta, 
2003).   
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Several mouse models of autoimmune disorders have been studied with 
regards to endocrine disorders. The most common ones are the NOD mice in which 
type I diabetes and sialitis develops spontaneously, and mice that have undergone 
neonatal thymectomy where massive infiltrates of lymphocytes in several organs lead 
to thyroiditis and gastritis (Eisenbarth and Gottlieb, 2004). 
 
1.4 AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE I 
Autoimmune polyendocrine syndrome type I (APS I) also called autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an autoimmune 
primary immunodeficiency caused by mutations in the AIRE gene, leading to multiple 
organ destruction (Ahonen et al., 1990; Nagamine et al., 1997). APS I was first 
described in 1929 in a study of the association between hypoparathyroidism and 
chronic candidiasis (Thorpe and Handley, 1929). Since then APS I have been widely 
studied throughout the years in relation to both genetics and autoimmunity because of 
its monogenic recessive mode of inheritance, thus making it a very valuable model for 
autoimmune diseases in general.  
 
1.4.1 Prevalence and genetics  
APS I is a rare autosomal recessive inherited disease more prevalent in certain 
historically isolated populations; Iranian Jewish (1:9000), Sardinian (1:14500) and 
Finnish (1:25000) populations (Björses et al., 1998; Rosatelli et al., 1998; Zlotogora 
and Shapiro, 1992). The disease is also relatively common in Slovenia (1:43000), 
Norway (1:80000) and Poland (1:29000) compared to the rest of the world where, only 
isolated cases are seen (Myhre et al., 2001; Podkrajsek et al., 2005; Stolarski et al., 
2006).  
Individuals with APS I display a high variability in their clinical features 
both among the patient group and also between family members and, thus, hint that 
despite the monogenic inheritance of the disease other genetic and non-genetic factors 
influence its clinical expression (Gallo et al., 2013). A prominent example of an 
intrafamilial variability was recently seen in two siblings carrying the same mutation 
but with strikingly different disease manifestations. The younger sister had a very mild 
disease, while the older brother displayed a progressive and severe disease affecting 
nearly every organ leading to life-threatening encephalopathy (Capalbo et al., 2012). 
An HLA association is not found in APS I. However specific HLA haplotypes are 
associated with alopecia and Addison’s disease in APS I patients, although HLA does 
not have any influence on the autoantibody formation characteristically seen in APS I 
(Gallo et al., 2013).  
Compared to most autoimmune diseases there are no major gender 
differences in the prevalence of APS I (Perheentupa, 2006). However, it has been 
reported that female APS I patients have a slightly increased predisposition for 
hypoparathyroidism compared to males (Gylling et al., 2003).   
The localization of the disease causing gene in APS I patients, AIRE, lead 
to the identification of a nonsense mutation, R257X, which is a C to T transition found 
in 85% of the Finnish APS 1 patients (Björses et al., 1998). This mutation was later 
found also in the majority of APS I patients in Italy, Norway, UK, and USA (Heino et 
al., 1999b; Pearce et al., 1998; Peterson et al., 2004). In contrast, an Y85C mutation is 
the major mutation among Iranian Jews a mutation absent in other countries. This 
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mutation is thought to induce a dimerization defect instead of resulting in a truncated 
protein as is seen in the common Finnish mutation R257X. In addition, the Y85C 
mutation is thought to be the reason for the milder form of APS I among Iranian Jews, 
typically without the presence of candida infections and fewer disease manifestations, 
as compared to Finnish APS I patients (Björses et al., 2000). However, the genotype 
correlation to disease manifestation in APS I is still very unclear, where the only 
correlation is seen in the presence of candida infections. Apart from the Y85C 
mutation, one more mutations seem to give a much milder candida infection (Kisand et 
al., 2010). To date over 60 APS I causing mutations in the AIRE gene have been found, 
most of them being nonsense or frameshift mutations leading to truncated polypeptides 
(Kisand and Peterson, 2011). 
  
1.4.2 Clinical phenotype 
As indicated above, patients with APS I suffer from a wide range of clinical 
manifestations with varying severity and disease components. The manifestations 
include both endocrine and non-endocrine disorders and can be up to 10 different 
disease manifestations in one single patient. However, the order in which these 
manifestations appear in the patients is very consistent (Ahonen et al., 1990; Husebye 
et al., 2009; Perheentupa, 2006). The first clinical symptoms of the disease are usually 
the infections of C. albicans leading to chronic mucocutaneous candidiasis (CMC) 
which is seen in 75-93% of the patients (Kisand and Peterson, 2011). The candida 
infections are typically followed by hypoparathyroidism and adrenocortical failure 
(Addison’s disease) at age four to five (Perheentupa, 2006). The presence of at least 
two of these three above mentioned diseases are used for the diagnosis of APS I that is 
further verified by genetic testing and serological screening of autoantibodies (Blizzard 
and Kyle, 1963; Buzi et al., 2003). As the disease progresses, the patients usually 
continue to acquire several additional syndromes, such as chronic diarrhea, keratitis, 
autoimmune hepatitis, rashes with fever, alopecia and vitiligo (Husebye et al., 2009). It 
is common that by the age of 30 many APS I patients have up to 10 different disease 
components. The most common endocrine manifestations apart from Addison’s disease 
and hypoparathyroidism are IDDM, hypogonadism, autoimmune thyroid disease and 
ovarian and testicular failure. Except for the already mentioned disease components 
alopecia and vitiligo, also enamel hypoplasia, keratoconjunctivitis and nail dystrophy 
belongs to the non-endocrine manifestations often seen in APS I (Perheentupa, 2006).  
The most prevalent and most peculiar of all manifestations in APS I 
seems to be the CMC infections. CMC is a selective immunodeficiency that usually 
affects the oral mucosa, but also the esophageal and vaginal mucosa and the intestine. 
The yeast sometimes also spread from the mouth to the hands and nails. The CMC 
infections in APS I patients are superficial and rarely develop into systemic infections, 
but if left untreated the chronic inflammation may develop into squamous cell 
carcinoma (Rautemaa et al., 2007). Recently, it has been shown that APS I patients lack 
the anti-fungal peptide cystatin SA1, due to destruction of the submandibular glands 
(Lindh et al., 2012). An overview of the most common manifestations and their 
prevalence in APS I patients in Finland, Norway and Italy are summarized in Table 1. 
To date, the treatments for APS I consist of hormonal replacement for the 
endocrine manifestations and aggressive antifungal treatment of CMC. 
Immunosuppressive treatment for some of the non-endocrine disorders has been tried in 
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small series of patients (Akirav et al., 2011; Husebye et al., 2009). The efforts are 
usually directed at ameliorating the different disease components as separate diseases, 
therefore, disease monitoring of all of the manifestations in a patient with APS I is 
utterly important. A number of manifestations other than CMC can develop into fatal 
disease such as chronic hepatitis, autoimmune gastritis and Addisons’s disease 
(Husebye et al., 2009; Perheentupa, 2006).  
Except for adequate clinical monitoring of APS I patients, the 
psychological burden of carrying such a severe disease with the stress of constant 
appearing and recurrent manifestations is also important to monitor. Support from 
family or a support counselor may account for a better life quality for APS I patients 
(Husebye et al., 2009).  
 
 
Table 1. Frequency (%) of disease manifestations in APS I patients in Finland 





1.4.3 Autoantibodies in APS I 
In association with the disease manifestations in APS I, circulating tissue-specific 
autoantibodies are the hallmark of the disease (Eisenbarth and Gottlieb, 2004). The 
presence of autoantibodies in APS I was first discovered in 1963 by detection of 
autoantibodies against the adrenals and thyroid in a patient with Addison’s disease 
(Blizzard and Kyle, 1963). Since then, several of the APS I associated autoantibodies 
and there corresponding autoantigens have been identified. The autoantibodies are 
typically directed against a specific antigen of a damaged organ or tissue and mainly of 
the IgG subclass. The autoantibodies are often present before the clinical manifestations 
Disease manifestation Finland Norway Italy 
Diagnostic triad 
CMC 100 85 83 
Hypoparathyroidism 87 85 93 
Addison’s disease 81 80 73 
Other endocrine manifestations 
IDDM 23 0 2 
Hypogonadism 69f28m 31 43 
Hypothyroidism  21 10 10 
Malabsorption 18 10 15 
Autoimmune hepatitis 18 5 20 
Pernicious anemia 13 - 15 
Other non-endocrine manifestations 
Enamel hypoplasia 77 40 - 
Alopecia 39 40 37 
Vitiligo 31 25 15 
Keratoconjunctivitis 22 10 12 
Nail dystrophy 52 10 - 
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are visible and can therefore be used for prediction of APS I (Eisenbarth and Gottlieb, 
2004).  
Several of the identified autoantigens in APS I are key enzymes in 
hormone synthesis. Among the best characterized are a group of cytochrome P450 
steroidogenic enzymes such as 21 hydroxylase (21-OH) in the adrenal cortex and side-
chain cleavage enzyme (SCC) and 17α-hydroxylase (17α-OH) in the adrenal cortex and 
in the gonads and also aromatic L-amino-acid decarboxylase (AADC) and P450c1A2 
in the liver (Gebre-Medhin et al., 1997; Krohn et al., 1992; Uibo et al., 1994; Winqvist 
et al., 1993; Winqvist et al., 1992). Another group of well characterized autoantigens 
are enzymes involved in neurotransmitter synthesis such as glutamic acid 
decarboxylase 65 (GAD65) in the pancreas, tryptophan hydroxylase (TPH) in the 
intestine and the tyrosine hydroxylase (TH) in hair follicles (Ekwall et al., 1998; 
Hedstrand et al., 2000; Velloso et al., 1994).  Many of the autoantigens in APS I are 
also found in the isolated autoimmune diseases, i.e. 21-OH in Addison’s disease and 
GAD65 in IDDM whereas others autoantigens are specific for APS I, such as TPH and 
SCC (Ekwall et al., 1998; Winqvist et al., 1993; Winqvist et al., 1992). An overview of 
the different autoantigens in APS I and their respective organ or tissue expression is 
depicted in table 2.  
 
Table 2. Autoantigens in tissues and organs of APS I patients. 
 
 
The prevalence of specific autoantibodies varies greatly between APS I 
patients, probably reflecting the variations in disease manifestations. Also, some 
individuals with APS I display tissue specific autoantibodies without any signs of 
clinical disease. Some autoantigens are, though, more frequently occurring than others. 
In a study of 90 Finnish, Swedish and Norwegian APS I patients it was revealed that 
the presence of autoantibodies against 21-OH, SCC and AADC was seen in 89% of the 
patients (Söderbergh et al., 1996). 7% of the patients displayed autoantibodies against 
insulinoma associated tyrosine phosphatase like protein (IA-2) and 37% had 
autoantibodies against GAD65, although IA-2 is a prevalent autoantibody in isolated 
IDDM (Söderbergh, 2004). Surprisingly, autoantibodies against interferon (IFN), in  
particular IFN-α and IFN-ω were found in all Finnish and Norwegian APS I patients 
(Meager et al., 2006b). These antibodies were later found to neutralize the action of 
IFN in vitro, but a functional role in mediating disease pathology for these 
autoantibodies was questioned (Akirav et al., 2011). Furthermore, the presence of 
Tissue/organ Disease manifestation Autoantigen 
Adrenal cortex Addison’s disease 21-OH, SCC, 17α-OH 
Thyroid gland Hypothyroidism Thyroid peroxidase, thyroglobulin 
Gonads Hypogonadism SCC,17α-OH 
Pancreas IDDM GAD65, AADC, IA-2, insulin 
Liver  Autoimmune hepatitis P450c1A2, P4502A6, AADC 
Parietal cells Gastritis H/K ATPase 
Intestine Intestinal dysfunction Tryptophan hydroxylase, histidine 
decarboxylase 
Hair follicle Alopecia Tyrosine decarboxylase 
Melanocytes Vitiligo SOX9, SOX10 
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autoantibodies against Th17 related cytokines as IL-22 and IL-17 have been reported in 
APS I patients. Interestingly, these autoantibodies have been associated with CMC 
infections (Kisand et al., 2010; Puel et al., 2010).  
 
1.5 THE AUTOIMMUNE REGULATOR 
Mutations in the autoimmune regulator (AIRE) gene were found to be the causative 
agent of APS I approximately 15 years ago, when two groups independently cloned the 
AIRE gene and localized it to chromosome 21q22.3 (Consortium, 1997; Nagamine et 
al., 1997). Two years later the mouse Aire homologue was cloned and mapped to 
chromosome 10. The mouse Aire gene was shown to share 73% homology with human 
AIRE (Blechschmidt et al., 1999; Wang et al., 1999). 
 
1.5.1 Molecular biology 
Currently, three different splice variants of the human AIRE protein and eleven 
different variants of the mouse Aire protein have been identified by alternative splicing, 
where one of the variants are found in both species (Ruan et al., 1999). However, the 
human and mouse AIRE protein share striking similarities in both genetic sequence and 
structural organization (Gallo et al., 2013).  
The AIRE protein is mainly found in the cell nucleus in specific nuclear 
bodies that forms a distinct speckled pattern, characteristic for transcription factor and 
thus AIRE is suggested to be involved in regulation of gene transcription (Björses et al., 
2000). AIRE also contains several conserved structural domains that further support 
AIREs role as a transcriptional regulator. Three of the identified domains are also found 
in proteins of the Sp100 family that are known to interact with DNA-binding proteins. 
These domains include a SAND domain thought to be important for the transactivating 
capacity of AIRE and its subcellular localization (Ilmarinen et al., 2005). At the N-
terminal region resides a caspase recruitment domain (CARD), formerly identified as a 
homologous staining region (HSR), at the N-terminal region important for dimerization 
(Ferguson et al., 2008). Finally, at the C-terminal domain of AIRE two separate plant 
homeodomains (PHD) with zinc finger motifs are found, thought to be DNA-binding 
(Consortium, 1997). Moreover, AIRE contains four interspersed LXXLL domains 
found in many transcriptional co-activators and a nuclear targeting signal (NTS) 
thought to be able to localize AIRE to the nucleus (Consortium, 1997; Savkur and 






Figure 2. Schematic of the functional domains of the AIRE protein. 
 
 
Two independent studies have indicated that AIRE may take part in the 
elongation step of transcription, but the exact molecular mechanisms for Aire’s 
function in transcriptional regulation remains to be determined (Org et al., 2008; Oven 
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et al., 2007). Perhaps the interaction of AIRE with other proteins may reveal parts of 
the story. The first identified protein to interact with AIRE was the CREB-binding 
protein (CBP), a histone and nonhistone acetylase that binds to the LXXLL domain of 
AIRE and activates transcription (Pitkänen et al., 2000). AIRE has also been found to 
bind to DNA protein kinase (DNA-PK) and deficiency of DNA-PK has been found to 
lead to decreased levels of tissue specific antigens in mTECs in the thymus (Liiv et al., 
2008). A functional interaction for AIRE and the protein inhibitor of activated STAT1 
(PIAS1) in transcriptional regulation of signal transducers and activator of transcription 
1 (STAT1) targeted genes have been identified (Ilmarinen et al., 2008). Furthermore, 
AIRE has been found to bind to and recruit complexes of the positive transcription 
elongation factor b (P-TEFb) to RNA polymerase II (Oven et al., 2007). In 2009, a 
large study on AIRE’s interaction with an array of different proteins was performed 
that identified about 20 different proteins that directly or indirectly interacted with 
AIRE (Abramson et al., 2010).  
 
 
1.5.2 Expression of AIRE/AIRE 
Since the cloning of the AIRE gene, its expression in different organs and cells has been 
widely studied. Hence, expression of AIRE in humans and mice have been found in 
different myeloid and epithelial cells in various tissues involved in autoimmune 
reactions such as in the thymus, spleen, lymph nodes and in the bone marrow. The 
expression of human and mouse AIRE are found at similar locations, with a few 
exceptions, given that the accessibility of organs and tissues are greater in mice than in 
humans. However, the greater challenge with the mapping of AIRE expression are the 
contradictory results from different investigations, both when it comes to the transcript 
and protein expression of AIRE.  
When it comes to primary lymphoid organs, it is well established that 
AIRE expression is found in the thymus, but expression has also been found in the 
bone marrow (Anderson et al., 2002; Halonen et al., 2001). In peripheral organs AIRE 
expression has been localized to lymph nodes, spleen and fetal liver (Adamson et al., 
2004; Gardner et al., 2008; Halonen et al., 2001; Heino et al., 1999a). In addition, Aire 
transcript has been found in the heart, kidney, skeletal muscle, lung, ovary and testis 
(Adamson et al., 2004; Heino et al., 2000). AIRE expression has not been found in any 
of the target organs in APS I (Björses et al., 1999; Heino et al., 1999a).  
The highest level of AIRE expression is found in mTECs in the thymus 
and some groups claim that this is the only location for AIRE expression (Hubert et al., 
2008; Mathis and Benoist, 2009). However, AIRE/Aire expression has also been found 
in several peripheral cells, such as subsets of stromal cells and DCs in spleen and 
lymph nodes (Fletcher et al., 2010; Gardner et al., 2008; Hubert et al., 2008; Pöntynen 
et al., 2008). Among these cell types AIRE protein has so far only been found in pDCs 
in the spleen and extrathymic stromal cells, eTACs, in lymph nodes and spleen 
(Gardner et al., 2008; Grupillo et al., 2012). AIRE protein has also been found in B 
cells and monocytes in peripheral blood, in particular in CD14+ monocytes (Kogawa et 
al., 2002; Suzuki et al., 2008). To date, the only AIRE expressing cell that has been 
proven to have a mechanistic role in regulating tolerance through AIRE is the mTEC in 
the thymus (Liston et al., 2003; Zuklys et al., 2000).  
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One aspect of AIRE/Aire expression that has not been as intensively 
studied is the actual induction or regulation of the gene or protein. However, a few 
studies have been made on the induction of Aire in mTECs. Several conflicting reports 
have been published on Aire induction and lymphotoxins. One group demonstrated that 
signaling through the lymphotoxin β (LTβ) receptor regulated Aire expression and PTA 
gene transcription, without changing the structure of the thymus epithelium (Chin et al., 
2003; Zhu et al., 2006). Another group showed that LTβ receptor signaling was 
required for accurate mTEC differentiation but showed no impact on Aire expression 
(Boehm et al., 2003). The latter was supported by groups showing that LTβ may induce 
PTA expression in Aire negative mTECs (Seach et al., 2008; Venanzi et al., 2007). 
Also, the RANK/RANK ligand pair and its downstream signal transducers TNF 
receptor-associated factor 6 (TRAF6) and NF-κB inducing kinase (NIK) have been 
found to have an effect of the generation of AIRE positive mTECs. Both the soluble 
RANK ligand and surface bound CD40 ligand were needed for the generation of AIRE, 
but it has not been shown whether RANK signaling induce Aire transcription 
independently of mTEC differentiation (Akiyama et al., 2008; Hikosaka et al., 2008). 
Further, some of the transcription factors belonging to the Ets family have been shown 
to positively activate Aire transcription (Meager et al., 2006a). 
 
1.5.3 Aire deficient mice 
Before the cloning of the murine Aire gene, several animal models were used to study 
the phenotype of APS I. White leghorn chicken, mice infected with cytomegalovirus, 
BioBreeding rats and NOD mice were among those models that developed some of the 
manifestations seen in APS I (Ikegami, 2002). However, the generation of Aire 
deficient mice made the research on APS I take leaps forward.  
The two first Aire deficient mice were made in 2002 by two independent 
groups and were of a mixed 129/Sv and C57BL/6 background (Anderson et al., 2002; 
Ramsey et al., 2002). The mouse made by Ramsey et al., was engineered to mimic the 
most common human Finnish mutation, R257X (Björses et al., 1998). The Aire gene 
was knocked out with the insertion of a neomycin-cassette (termination codon) in the 
beginning of exon 6. The phenotype of this mouse was relatively mild with no signs of 
clinical endocrine disease, but infiltrates of lymphocytes in several organs, atrophy of 
thymus and adrenals, infertility and organ specific circulating autoantibodies were 
observed. In addition, the mice displayed increased T cell proliferation after 
immunization with hen egg lysozyme (HEL) antigen and a change in the distribution of 
the TCRVβ chain families (Ramsey et al., 2002). This mouse was later crossed onto 
several double transgenic mouse models. The first model expressed HEL as an organ 
specific antigen under the control of the rat insulin promoter (RIP) and T cells 
expressing a TCR specific for HEL. Studies on this mouse model confirmed the role of 
Aire in tolerance mechanisms by demonstrating that Aire is needed for deletion of 
autoreactive T cells in the thymus (Liston et al., 2003). Second, the Aire deficient mice 
were crossed to a similar system, where the HEL antigen was instead expressed under 
the control of the thyroglobulin promoter. These mice displayed a decreased thymic 
expression of endogenous insulin and an increased presence of islet specific-T cells in 
the spleen (Liston et al., 2004). This mouse was later backcrossed to a congenic 
C57BL/6  background that displayed normal endocrinology, but infiltrates of B cells in 
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the liver and MZB cell lymphomas developed when reaching above 15 months of age 
(Hässler et al., 2006).  
The second Aire deficient mouse was created by Anderson et al., using 
conditionally targeted disruption of exon 2 and parts of the surrounding introns 
(Anderson et al., 2002). This induced knock-out displayed some differences in 
phenotype with the Ramsey model. Lymphocytic infiltrates of salivary glands, ovarian 
follicles and the retina of the eye, and autoantibodies against these targets were found. 
Gene array analysis of mTECs from these mice displayed a reduction of some tissue 
specific antigens in the absence of Aire. Among the reduced antigens were insulin, 
salivary protein 1 and fatty acid binding protein. Furthermore, bone marrow transfer 
experiments and thymic transplants in these mice revealed that Aire is important for the 
prevention of autoimmunity (Anderson et al., 2002). Later, a similar model of the HEL 
transgene, though with ovalbumin as an antigen, was crossed to this Aire deficient 
mouse. This model showed a defect in the regulation of negative selection of OT-II T 
cells (Anderson et al., 2005). Further, the original Anderson mouse have also been 
backcrossed onto several different strains including C57BL/6, BALB/c, NOD and SLJ. 
These mice displayed some differences in phenotypes that may reflect the disease 
varieties between APS I patients. For example, the C57BL/6 and BALB/c mice 
displayed a mild phenotype compared to the one seen on the mixed 129/sv and 
C57BL/6  background, while the Aire deficient mice on the NOD and SLJ background 
had a more severe phenotype with a higher magnitude of lymphocytic infiltrates and 
the occurrence of pancreatitis and thyroiditis. Surprisingly, autoreactivity in these mice 
was seen against the exocrine cells of the pancreas and not against the β-cells (Jiang et 
al., 2005).  
In 2005, a third Aire deficient mouse was generated by targeting of exon 
5 to 12 and backcrossed onto the C57BL/6  and BALB/c background. Similarly to the 
two previous Aire deficient models, this mouse also displayed reduced fertility and 
infiltrates of lymphocytes. However, these mice also displayed a reduction in tear fluid 
and autoreactivity against α-fodrin, an antigen found in Sjögren’s syndrome. In 
addition, the Aire deficient mice on the BALB/c background showed infiltrates of 
lymphocytes in the gastric mucosa and autoantibodies against this tissue (Kuroda et al., 
2005). A year later this Aire deficient model was backcrossed onto the NOD 
background. These mice exhibited reduced body weight and lymphocytic infiltrates of 
several organs. In addition, the autoreactivity against the pancreas was directed at 
exocrine cells, the acinar cells surrounding the β-cells. The presence of diabetes that is 
found in normal NOD mice did not develop in the Aire deficient NOD mice and might, 
thus, be explained by the non-reactivity against insulin and the β-cells (Niki et al., 
2006).  
A fourth Aire deficient mice was created to mimic the second most 
common human mutation in APS I patients, a 13 base pair deletion that disrupts the 
PHD domain in exon 8. In addition to a similar mild phenotype as the previously 
described Aire deficient mice on a B6 background, these mice also displayed an 
increased frequency of activated MHC class II expressing  mTECs in the thymus and a 
reduction in the immature MECs (Hubert et al., 2009).  
One double Aire knock-out mice has been described. Scurfy mice, 
deficient in FoxP3, on the C57BL/6 background were crossed with Aire deficient mice 
with the exon 2 deletion on a C57BL/6 or NOD background. These mice exhibited 
severe lymphocytic infiltrates of the liver and the lungs, approximately 14 days after 
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birth, resulting in death or early termination at 28 days of birth. Surprisingly, other 
tissues remained healthy and no presence of autoantibodies was found. Not 
surprisingly, though, the double-knockout mice on the NOD background developed an 
even more severe manifestation of disease in the liver and lungs than the C57BL/6  
(Chen et al., 2005).   
In addition, a knock-in mouse giving rise to a dominant negative Aire 
mutation, G228, has been constructed on the C57BL/6 and the NOD background. 
These mice displayed a global suppression of tissue specific antigens and developed a 
novel phenotype with autoimmune thyroiditis and peripheral neuropathy (Su et al., 
2008). A summary of the different Aire deficient mice is given in table 3.  
 
 
Table 3. Aire deficient mouse models. 
 
 
Several of the findings in all of these Aire deficient mice suggest 
differences in the immunopathogenic mechanisms between the mice models and the 
human individuals with APS-1. One of them is the fact that the Aire deficient mice 
have a much milder phenotype than the human patients, with the NOD Aire deficient 
mice being the only one to develop autoimmune disease, suggesting that Aire deficient 
mice are lacking an environmental trigger or additional disease susceptibility genes 
(Hubert et al., 2009; Kuroda et al., 2005). It has been suggested that the captivity of 
Targeted exon Background Major findings 
Exon 6 (Ramsey et 
al., 2002) 
Mixed  C57BL/6 /129 
Liver infiltrates of lymphocytes, autoantibodies, 
increased response against HEL, altered TCRβ 
repertoire. 
Exon 6 (Hässler et 
al., 2006) 
C57BL/6 
MZB cell lymphoma, liver infiltrates of B cells, 
normal endocrinology. 
 
Exon 2 (Anderson 
et al., 2002) 
Mixed  C57BL/6/129 
Infiltrates of lymphocytes in salivary glands, 
ovaries, stomach and eye, differentialy 
regulated genes in mTECs. 
Exon 5-12 (Kuroda 
et al., 2005) 
C57BL/6  and BALB/c 
Autoreactivity against α-fodrin, infiltrates of 
lymphocytes in gastric mucosa, reduction in tear 
fluid. 




Organ infiltrates depending on background, 
exocrine pancreatitis in NOD and SJL. 
 
Exon 2 (Chen et al., 
2005) 
FoxP3-/- C57BL/6 
Death at 28 days of age, severe lymphocytic 
infiltrates of lung and liver, no autoantibodies. 
 
Exon 5-12 (Niki et 
al., 2006) 
NOD 
Exocrine pancreatitis, protection against 
diabetes. 
 
Exon 8 (Hubert et 
al., 2009) 
C57BL/6 
Increased levels of activated mTECs in thymus, 
reduction of immature mTECs 
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Aire deficient mice under specific pathogen free conditions account for the mild 
phenotypes and would for example explain the absence of mucocutaneous candida 
infections in the Aire deficient mice (Mathis and Benoist, 2009). Furthermore, it has 
been shown that Aire deficient mice do not develop the same type of autoantibodies as 
APS I patients, since the autoantibodies produced are not directed towards the most 
common organs destroyed in APS I (Pöntynen et al., 2006). For example the liver is the 
most common target organ in Aire deficient mice which is very rarely affected in APS1 
patients (Ramsey et al., 2002; Söderbergh et al., 2004).  
 
1.5.4 Aire function in mice and men 
The findings that mTECs expressed high levels of AIRE along with a wide range of 
TSAs raised the speculations that AIRE could be involved in the regulation of central 
tolerance in the thymus (Blechschmidt et al., 1999; Derbinski et al., 2001). Also, the 
AIRE protein was found to have regulatory elements resembling that of transcription 
factors (Björses et al., 1999). Hence, AIREs role in central tolerance was established 
when absence of AIRE in transgenic mouse models lead to impaired deletion of tissue 
specific antigens in the thymus. This was demonstrated by several groups using TCR 
transgenic Aire deficient mice (Anderson et al., 2005; Liston et al., 2003). The deletion 
of autoreactive T cells in the thymus has also been shown to be Aire dose-dependent, 
since deletions induced by antigens under control of the thyroglobulin promoter in 
homozygous Aire mice was less efficient than in Aire heterozygous mice (Liston et al., 
2004). The fact that Aire deficient mice do not develop antibodies against insulin or any 
of the autoantigens seen in APS I patients raise the question that AIRE in mice and 
humans may not have the same function (Pöntynen et al., 2006). Also, Aire deficient 
mice on the NOD background led to the development of exocrine pancreatitis and not 
diabetes (Jiang et al., 2005). In contrast, reduced expression of the stomach antigen 
mucin 6 and the eye antigen interphotoreceptor retinoid-binding protein (IRBP) in the 
thymus was shown to also appear as autoantigens in the periphery, displaying a direct 
cause and effect function for Aire in mice (DeVoss et al., 2006; Gavanescu et al., 
2007). However, the Aire deficient mice do also show autoreactivity to autoantigens 
that are expressed at normal levels in the thymus as alpha-fodrin and a pancreas 
specific protein disulphide isomerase (Kuroda et al., 2005; Niki et al., 2006).  
Functions of AIRE in the thymus other than regulating negativeselection 
through expression of TSAs have been proposed. For example, AIRE has been 
implicated to play a role in the differentiation of mTECs (Derbinski et al., 2005). On 
the other hand, AIRE expression seems to be dependent on a proper thymic 
composition, since mice with disrupted thymic epithelium and medulla lack mTECs 
and AIRE expression, as observed for example in RelB deficient mice (Heino et al., 
2000). Furthermore, absence of AIRE and or mTECs leads to a block in the 
development of CD4+ T cells in the thymus (Li et al., 2007). Also, Aire has been shown 
to regulate the expression of co-stimulatory molecules important for both maturation 
and migration of thymocytes. For example, Aire deficient mice have reduced 
expression of CCL22 in the thymus and thus implies that Aire is needed for the 
migration of DP T-cells to the medulla (Anderson et al., 2005). In contrast, CCL19 and 
CXCL10, expressed at the cortico-medullary junctions luring SP T cells to migrate to 
the blood, are increased in Aire deficient mTECs (Annunziato et al., 2001). 
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Aire deficiency has also been found to affect other cell types that develop 
in the thymus. It has been shown that TSA expression in the thymus is able to 
positively select Tregs, which raised the question whether this is an AIRE dependent 
event. At first, several Aire deficient mouse models showed normal Treg function and 
number (Anderson et al., 2002; Kuroda et al., 2005). However, a later study showed 
that AIRE positive mTECs targeted with a particular antigen were able to induce Tregs 
with the same antigen specificity (Aschenbrenner et al., 2007). Several recent reports 
have been able to further establish Aires role in clonal deletion and differentiation of 
Tregs (Lei et al., 2011; Malchow et al., 2013). In addition, Treg function in APS I 
patients were found to be impaired (Kekäläinen et al., 2007).   
Furthermore, it has been shown that the development of invariant NKT 
(iNKT) cells is dependent of Aire. A recent study showed that Aire deficient mice 
displayed a reduction of iNKT cells in both thymus and peripheral organs a finding 
confirmed also in APS I patients who displayed a reduction of iNKT cells in peripheral 
blood (Lindh et al., 2010).      
Apart from the expression of AIRE in mTECs AIRE is also expressed in 
the periphery and thus, AIRE is implicated to play a role in peripheral tolerance. In the 
periphery AIRE expression is mainly found in subsets of DCs in lymphoid organs and 
monocytes in peripheral blood (Grupillo et al., 2012; Kogawa et al., 2002). Thus, both 
APS I patients and Aire deficient mice have shown increased antigen presenting cell 
mediated T cell activation in spleen and lymph nodes. Further, microarray experiments 
on stimulated DCs from Aire deficient mice has pointed out several differentially 
regulated genes that could be involved in the activation of T and B cells. One of these 
are the vascular cell adhesion molecule-1 (VCAM-1) expressed on endothelial cells and 
lymphoid DCs (Ramsey et al., 2006). Also, immunization of Aire deficient mice with 
HEL antigen leads to a hyperproliferative T cells response (Ramsey et al., 2002).  
Furthermore, the presence of marginal zone lymphomas has been 
reported in aged Aire deficient mice which imply an increased activation of MZB cells 
in the absence of Aire (Hässler et al., 2006). It has also been shown that depletion of B 
cells with anti-CD20 monoclonal antibody ameliorate the autoimmune pathology of 
Aire deficient mice (Gavanescu et al., 2008).  
Murine AIRE expression has also been found in stromal cells in lymph 
nodes. These AIRE expressing stromal cells were suggested to be involved in TSA 
presentation to CD8+ T cells, however some of the key TSAs, such as insulin were not 
expressed by these cells (Lee et al., 2007). However, in a second report AIRE 
expressing stromal cells were found at the T and B cell border in lymph nodes and 
spleen. These extrathymic stromal cells, were found to mediate deletion of autoreactive 
T cells and found to express some of the TSAs expressed by mTECs in the thymus 
(Gardner et al., 2008).   
In summary, AIRE has been established to play an important role in 
mediating central tolerance in the thymus. Emerging evidence also point at a role for 
AIRE in the periphery and hopefully future research will aid in the understanding of 
Aires mechanism in peripheral organs.   
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2 PRESENT STUDY 
 
The aim of this study was to investigate the role of AIRE in peripheral tolerance 
mechanisms by the use of Aire deficient mice in order to improve our understanding on 


































A detailed description of the materials and methods used in the following studies are 
given in the original papers, I-IV. 
 
Mice (Paper I-IV)    
The generation of Aire-/- mice (B6.129s4-Airetm1P1tn) has been described previously 
(Ramsey et al., 2002). In addition, congenic Aire+/- C57BL/6 mice crossed with OTII 
TCR transgenic C57BL/6 mice, or OTII TCR transgenic C57BL/6 mice alone were 
used with the permission of Dr F. Carbone (Paper I and II). All Aire-/- mice used were 
age- and sex matched with wild type littermates from heterozygotic breeding as 
controls. Athymic BALB/c nude mice were from Charles River Laboratories. The mice 
were kept at the animal facility at the Department of Microbiology, Tumour and Cell 
Biology, Karolinska Institutet.  
 
Patients (Paper I-IV) 
Blood was collected from APS I patients and used with their informed consent (Paper 
I). PBMCs were collected from healthy blood donors by automated leukapheresis and 
used with their informed consent (Paper II-IV). Blood and bone marrow were collected 
from patients undergoing total hip arthroplasty surgery and used with their informed 
consent (Paper IV). 
 
Immunizations (Paper I-IV)  
Mice were injected subcutaneously with Flt3L transfected tumor cells 14 days before 
sacrifice (Paper II-IV). Mice were immunized i.p. with TNP-ficoll (Paper I) and 
NP(23)-CGG in  alum (Paper II), serum was collected before and after immunization.  
 
Bone marrow transfer experiment (Paper I) 
Bone marrow cells were obtained from flushed mouse femurs. Bone marrow transfer 
was performed by intravenous injection of donor-derived bone marrow cells into 
recipient mice irradiated with 900 rad 4 hours prior reconstitution (Paper I).  
 
Proliferation assay (Paper II) 
CFSE labeled CD4+ splenic OTII transgenic T cells were injected into mice 
intravenously 12 hours prior to intra peritoneal injection of DC-targeted antibody 
coupled to ovalbumin. Mice were sacrificed three days after i.p. injection.     
 
Flow cytometry (Paper I-IV) 
Single cell suspensions were prepared from murine spleen and bone marrow. Cells 
were stained with fluorochrome-conjugated antibodies and analyzed by flow 
cytometry, either on a FACSAria or a FACSCanto using FACS diva (Becton 
Dickinson) or FlowJo (TreeStar, Inc).  
 
Cell Sorting (Paper II, IV) 
Single cell suspensions were prepared from murine spleen and bone marrow. Cells 
were stained with bead-conjugated antibodies and sorted with magnetic beads either 
manually or with AutoMACS (Miltenyi Biotech). Magnetically sorted cells were 
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stained and sorted on a FACSAria (Becton Dickinson) or a MoFlo XDP (Beckman 
Coulter).  
 
ELISA and ELISPOT (Paper I-III)  
Levels of antigen specific antibodies were measured in serum from mice using specific 
ELISA kits according to manufacturer’s instructions. An ELISPOT assay was used to 
measure the numbers of IgM-secreting B cells (Paper I).  
 
Quantitative RT-PCR amplification (Paper I-IV) 
Total RNA was extracted with Trizol® reagent (Invitrogen) or Rneasy mini spin kit 
(Qiagen) and cDNA was synthesized by reverse transcription. Transcript levels were 
amplified using specific primers on an iCycler IQ Optical System or a TFX96 Touch 
Real-Time System (Bio-Rad). Quantitative RT-PCR array was prepared according to 
manufacturer’s instructions (SABiosciences/Qiagen) (Paper II, III).  
 
Immunofluorescent staining (Paper II) 
Immunohistochemistry was used to analyze protein expression in frozen tissue 
cryosections and single cells obtained by cytospin centrifugation. Immunofluorescence 
was documented using a confocal laser scanning microscope (Leica TCS SP2).  
 
Electrophoresis and immunoblotting (Paper I) 
Proteomic analysis was performed with 2-D electrophoresis, SDS page and 
immunoblotting.  
 
Statistical analysis (Paper I-IV) 
Data were analyzed with student’s T-test, Wilcoxon’s rank sum test or Mann-Whitney 
U test in order to test for differences between two groups. Mean values are given 
together with standard deviations. P<0.05 was considered significant.  
 
Ethical considerations 
All experiments involving animal procedures and use of human material were 
evaluated and approved by the local ethics committees and have been conducted 









2.2 RESULTS AND COMMENTS 
2.2.1 Absence of AIRE leads to increased B cell activation through 
defective STAT1 regulation 
Aire-/- mTECs display reduced levels of TSA expression in the thymus, a defect that 
would lead to the presence of autoreactive T cells in the periphery. However, the 
majority of the manifestations in the periphery of Aire-/- mice including autoantibodies, 
liver infiltrates of B cells and development of MZB cell lymphoma imply an increased 
activation of B cells (Hässler et al., 2006). In this study, Paper I, the activation of B 
cells in the absence of AIRE was investigated. Aire-/- mice were immunized with T cell 
independent antigen type I, TNP-Ficoll. The response to TNP-Ficoll is mainly 
dependent on MZB cells, demonstrated by a reduction of specific antibodies in 
immunized MZB cell deficient mice (Guinamard et al., 2000). When compared to wild 
type mice, Aire-/- mice displayed a significant increase in the production of TNP-
specific antibodies. Furthermore, the response was characterized by an increased 
activation of peripheral B cells, in particular the MZB cells. The distribution of all B 
cell subsets remained normal in the Aire-/- mice. Mice overexpressing the cytokine 
BAFF share the same characteristic B cell manifestations as observed in the Aire-/- mice 
(Mackay et al., 1999). In order to elucidate the mechanism behind the increased 
activation of MZB cells the levels of BAFF in Aire-/- mice and APS I patients was 
measured. Both mice and patients displayed significantly increased levels of BAFF in 






BAFF has been shown to be secreted by DCs and radio resistant stromal 
cells when stimulated with IFN-γ and is important for the activation and maturation of 
B-cells (Schneider et al., 1999). To exclude that the increased levels of BAFF were due 
to autoreactive T cells, the levels of BAFF expressing DCs were assessed in athymic 
nude mice reconstituted with bone marrow from Aire-/- mice or wild type mice. These 
experiments confirmed the intrinsic increase of BAFF in Aire-/- mice and importantly 
demonstrated that the production of BAFF by DCs is T-cell independent. The levels of 
BAFF secreted by Aire-/- bone marrow-derived DCs (BMDCs) were found to be further 
increased upon IFN-γ stimulation in vitro (Figure 4). There were no differences in the 
Figure 3. Increased BAFF in serum of APS I patients (left panel) and Aire-/- mice (right 
panel), measured with ELISA. Each dot represents one individual and mean values are 
indicated by horizontal lines. 
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levels of IFN-γ in the spleen of Aire-/- mice and wild type mice. In addition, in vitro 
stimulation of Aire-/- BMDCs with IL-10 revealed no differences in BAFF secretion 
compared to wild type BMDC, suggesting that IFN-γ is the main inducer of BAFF in 



















Upon engagement, the IFN-γ receptor signals through the STAT1 
pathway and regulates the expression of several genes. During the progress of this work 
it was shown that AIRE interacts functionally with the protein inhibitor of activated 
STAT1 (PIAS1) (Ilmarinen et al., 2008). This indicated that AIRE and PIAS1 might 
work together to inhibit downstream signaling of the IFN-γ receptor. We therefore 
suggest that altered signaling through STAT1 subsequently leads to increased secretion 
of BAFF in Aire-/- mice and in APS I patients. In line with this hypothesis, the STAT1 
regulated gene Gbp1 was found to be up-regulated in splenocytes from Aire-/- mice. 
 
Comments 
After the publication of this paper, the role of AIRE as a regulator of STAT1 signaling 
has been further investigated. The expression of several STAT1 regulated genes was 
found to be up-regulated in Aire-/- BMDCs (Figure 5). These genes have also been 
reported to be up-regulated in Pias1-/- mice (Liu et al., 2004). Furthermore, decreased 
levels of insulin has been reported in mTECs stimulated with IFN-γ (Levi and 
Polychronakos, 2009). More recently, another article by the same authors demonstrated 
an increase in the expression of several autoantigens, including insulin, in mTECs 
isolated from IFN-γ deficient mice. The expression of AIRE in these mice was also 
found to be increased (Levi and Polychronakos, 2013). The mechanism behind AIREs 
role in the regulation of TSAs in mTECs has not yet been fully established. However, 
these data suggest that AIRE regulates the IFN-γ signaling pathway and perhaps IFN-γ 
also regulates AIRE expression.  
The role of BAFF in mediating B cell survival and autoreactive B cells 
has been demonstrated in several autoimmune diseases and recently the human 
neutralizing anti-BAFF monoclonal antibody, Belimumab, was approved for the 
Figure 4. Production of BAFF from Aire-/- or wild type BMDCs after IFN-γ stimulation in 
vitro, measured with ELISA. Data represents mean values and SEM of four mice in each 
group and representative of two independent experiments. 
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treatment of SLE. However the treatment has so far only yielded moderate results and 















































Figure 5. Expression of the STAT1-targeted genes Gbp1, IRF8, CXCL9 and 
CXCL10 in Aire-/- and wild type BMDCs after IFN-γ stimulation measured by 
quantitative RT-PCR. Bars represent mean of 3 mice and errors bars represent 
SEM. 
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2.2.2 AIRE in marginal zone dendritic cells regulate peripheral 
immunity 
In this study (Paper II), the role of AIRE in peripheral DCs was further investigated. 
The expression profile of Aire in murine peripheral DCs subsets was investigated and 
revealed that AIRE is specifically expressed by DCs bearing the surface marker 33D1. 
33D1 is specifically expressed by DCs residing in the marginal zone of the spleen and 
bridging channels, areas that have been shown to influence both T and B cell tolerance 
(Dudziak et al., 2007; Finkelman et al., 1996). In support of this, it was found that the 
marginal zone DC subset expresses the autoantigen insulin, which was decreased in 
Aire-/- 33D1+ DCs (Figure 6). Furthermore, the inducible co-stimulator (ICOS) ligand 
was found to be up-regulated on Aire-/- 33D1+ DCs. These features are seen in AIRE 
expressing mTECs in the thymus and in AIRE expressing stromal cells in the spleen 
















The 33D1+ DC subset has also been implicated to be important for the 
maturation of plasmablasts in the extrafollicular areas of the spleen (García De Vinuesa 
et al., 1999). In accordance with this function, the chemokine CXCL12, known to be 
involved in the migration of plasma cells was found to be expressed by the 33D1+ DCs 
and down-regulated in Aire-/- 33D1+ DCs. In order to elucidate whether the decreased 
levels of CXCL12 affect the movement of cells within the structures of the spleen,  
Aire-/- mice were immunized with the T-cell dependent antigen, NP-CGG. The 
response against this antigen was found to be decreased in Aire-/- mice, which displayed 
a reduction of specific antibodies against IgG1 and IgG3. Also, the same antibodies 
were found to reside within germinal centers in the follicles of the spleen and not in the 
extrafollicular areas as seen in the spleens of wild type mice. Thus, we speculated that 
the low production of CXCL12 by Aire-/- 33D1+ DCs in the marginal zone was unable 
to support plasma cell migration out of the GC, which resulted in a haltered 
extrafollicular response to NP-CGG. Further, it was revealed that the Aire-/- mice 
displayed increased levels of Tfh cells and GCB cells after NP-CGG injection. The 
staggering of B cells in the follicles of Aire-/- mice, as well as the increased levels of 
BAFF and ICOSL on Aire-/- DCs may be the reason for the exaggerated numbers of B 
cells and T cells found in germinal centers. Also, a number of co-stimulatory factors on 
Figure 6. Expression of Ins2 in 
Aire-/- and wild type 33D1+ and  
CD8+ DCs measured by 
quantitative RT-PCR. Bars 
summarise three independent 
experiments, error bars 
represent s.d.   
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the Tfh cells and the GCB cells themselves likely contribute to the increased activation 







Just before the publication of this paper, an article confirming the role of the 33D1+ 
DCs in regulating extrafollicular T cell dependent responses was published (Chappell et 
al., 2012). Furthermore, mice that lack the receptor for CXCL12, CXCR4, display the 
same phenotype as the Aire-/- mice (Cyster, 2003). However, the mechanism behind 
AIREs regulation in these responses remains to be investigated. The localization of the 
33D1+ DCs in the marginal zone/red pulp area, makes it likely that this subset of DCs is 
involved in the exaggerated activation of MZB cells seen in aged Aire-/- mice (Hässler 
et al., 2006).  
Interestingly, ICOS mediated mechanisms have been found to influence 
the development of insulin-dependent diabetes in NOD mice (Hawiger et al., 2008). 
Also, anti-ICOSL antibodies have been used to inhibit B cell mediated autoimmunity 









Figure 7. Schematic of the different cytokines, ligands and receptors connecting the 33D1+ 
dendritic cells, the T-follicular helper cells and the germinal center B cells. Illustration 
courtesy of Dr. M. Winerdal. 
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2.2.3 IFN-γ regulates the expression of Aire in marginal zone DCs 
The previous findings, that AIRE is involved in regulating the STAT1 signaling 
pathway and that stimulation of Aire-/- BMDCs with IFN-γ leads to increased levels of 
BAFF, prompted the investigation for a similar role for the AIRE expressing 33D1+ 
DCs (Paper III). Similar to Aire-/- BMDCs, the 33D1+ DCs also displayed an increase 
of STAT1 targeted genes upon IFN-γ stimulation. The relationship between AIRE and 
IFN-γ have been further investigated by Levi and Polychronakos which have reported 
decreased levels of insulin in mTECs after stimulation with IFN-γ (Levi and 
Polychronakos, 2009). Since AIRE deficiency leads to decreased levels of insulin 
transcript (Ins2) similar to what is seen in wild type mice stimulated with IFN-γ, it was 
tempting to speculate that IFN-γ also affected the expression levels of Aire. Thus, IFN-
γ stimulation of 33D1+ DCs in vitro resulted in both decreased levels of Aire and Ins2 














Figure 8. Relative mRNA levels of Aire and Ins2 in 33D1+ DCs after IFN-γ stimulation in 
vitro, analyzed by quantitative RT-PCR. Data represents mean values of three independent 
experiments and error bars represent s.d. 
 
Furthermore, the down-regulation of Aire and Ins2 after IFN-γ was found 
to be transient, with a quick drop in expression two hours after stimulation followed by 
a restoration in expression after eight hours. In order to elucidate whether the down-
regulation of Aire and Ins2 in 33D1+ DCs is truly caused by IFN-γ, the transcript level 
of Aire was investigated in IFN-γ receptor deficient 33D1+ DCs. The expression of Aire 
was not down-regulated in the IFN-γ receptor deficient 33D1+ DCs, in fact, the levels 
were instead increased compared to wild type levels (Figure 9). This observation 
suggests that the levels of Aire in C57BL/6 mice are under the control of naturally 
occurring IFN-γ in steady state.  Since the down-regulation of Ins2 followed the down-
regulation of Aire, the possibility that a converse situation may be found in the IFN-γ 
receptor deficient mice. In line with this hypothesis, an increased level of insulin was 

























What regulates the expression of Aire has remained elusive for many years and so far 
no consisting data on this matter has been found. These results suggest that, not only 
does AIRE regulate the signaling of IFN-γ through the STAT1 pathway, but IFN-γ also 
regulates the level of Aire expression itself. Interestingly, a very recent publication 
demonstrated that mTECs from IFN-γ-/- mice do display increased levels of both Aire 
and Ins2 (Levi and Polychronakos, 2013).  
IFN-γ is mainly released by activated CD4+ T cells, NKT cells and NK 
cells during inflammatory responses. These findings suggest that Aire positive 33D1+ 
DCs present self-antigens during steady state, but upon activation Aire is down-
regulated and the DCs will shift to an immunogenic state and instead up-regulate the 
expression of chemokines and co-stimulatory molecules to aid in the response against 
foreign pathogens (Blanco et al., 2008; Torres-Aguilar et al., 2010). It remains to be 
investigated whether this situation is true during an inflammatory response in vivo. 
Figure 9. Relative expression of Aire in 33D1+ and CD8+ DCs sorted from spleen of wild type 
mice and IFN-γ receptor-/- mice analyzed by quantitative RT-PCR. Data represents mean 
values of two independent experiments and error bars represent s.d. 
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Figure 10. Schematic overview of the subtypes of dendritic cells and the markers used to 
identify each cell investigated in this study. MDPs, CDPs and pre-cDCs were sorted out from 
murine bone marrow. 33D1+ and CD8+ were sorted out from the spleen.  Illustration courtesy 
of Dr. M. Winerdal. 
2.2.4 Aire deficiency affects the expression of developmental genes in 
DCs  
In this study, paper IV, the role of Aire in the bone marrow precursors of dendritic cells 
was investigated. AIRE has been reported to be expressed in murine bone marrow and 
thus, raised the question whether the expression of Aire in the 33D1+ DCs is acquired 
already at a precursor stage in the bone marrow (Halonen et al., 2001). The tissue 
resident DCs and plasmacytoid DCs (pDCs) are derived from the common dendritic 
cell precursor (CDP) where they diverge into pre-pDCs and pre-cDCs, possibly under 
the influence of a set of transcription factors. The pre-cDCs are further delineated into 
CD8+, 33D1+ and DN DCs upon maturation in the spleen, however the fate of 
development into either one of these subsets is thought to be pre-programmed in the 
bone marrow. This decision is thought to be influenced by the induction of certain 
lineage specific transcription factors (Satpathy et al., 2011). The DC precursor stages 
were sorted out from murine bone marrow according to their expression of specific 
surface markers (Figure 10).  
 
 
Although lower than the expression in the fully differentiated 33D1+ DC 
subset, Aire expression was found in the pre-cDC subset in the bone marrow. However, 
the frequency and distribution of the pre-cDC subset appeared to be normal in the   
Aire-/- mice. Furthermore, the population of 33D1+ DCs in the spleen was found to be 
slightly decreased in the Aire-/- mice. This indicated that an alteration in the 
developmental step between the pre-cDC and 33D1+ population might be the problem. 
Therefore, the transcriptional factors thought to influence the development of splenic 
DC subsets in the bone marrow were investigated. Two of the transcription factors 
thought to be important for the development of the 33D1+ subset were found to be 
decreased in the Aire-/- 33D1+ DCs (Figure 11). Mice deficient in either of these 
transcription factors, i.e. IRF4 or RelB, display a marked reduction of the 33D1+ DC 
subset (Suzuki et al., 2004; Wu et al., 1998). However, the reduction of these genes in 
the Aire-/- 33D1+ DCs were only about 50%, but might explain the reduction of 33D1+ 
DCs in the spleen of Aire-/- mice.  
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Figure 11. Relative expression of developmental 
transcription factors in sorted 33D1+ and CD8+ 
DCs from Aire-/- and wild type mice analyzed by 
quantitative RT-PCR. Bars summarize three 
independent experiments and error bars represent 
s.d. 
 
Also, one gene that has not, so far, been shown to influence the 
development of 33D1+ DCs is IRF8. IRF8 is instead thought to be important for 
development of the CD8+ DC subset. Interestingly, IRF8 is a STAT1-targeted gene and 
thus induced by IFN-γ (Liu et al., 2004). The previous findings, that Aire-/- 33D1+ DCs 
display increased levels of STAT1-targeted genes upon IFN-γ, lead us to investigate the 
expression of IRF8 in the 33D1+ DC subset after IFN-γ stimulation. In accordance with 
our hypothesis, IRF8 was found to be up-regulated in the Aire-/- 33D1+ DCs after IFN-γ 
stimulation in vitro. Thus, we speculate that the slight reduction of 33D1+ DCs in the 
Aire-/- mice might be due to a rescue by the induced IRF8 expression in this subset.  
 
Comments 
Neither the induction of Aire, nor the factors affecting the regulation of dendritic cell 
commitment and differentiation have been well studied. In particular, how lineage 
transcription factors are regulated to determine DC diversification is largely unknown 
(Fierabracci, 2011; Satpathy et al., 2011). These data point at a role for AIRE in the 
regulation of lineage commitment transcription factors at the later stages of DC 
development in the bone marrow. Further investigation of AIREs role in regulating 
these transcription factors is needed. Also, investigations of the pre-cDC subset in 
blood of Aire-/- mice may reveal some clues.  
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Interestingly, the transcription factor RelB, which was found to be down-
regulated in the Aire-/- 33D1+ DCs, has also been implicated to influence the 
development of mTECs in the thymus. Further, RelB-/- mice lack AIRE expression and 
have an abnormal thymic architecture that lacks the medullary structure (Heino et al., 
2000).   
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2.3 GENERAL DISCUSSION 
Since the mouse Aire gene was discovered and the generation of Aire deficient mice 
began nearly 15 years ago, only a small part of the story behind the severe 
autoimmunity in APS I has been unraveled. When it comes to the function of AIRE it 
has been clearly established that AIRE is involved in the negative selection of 
autoreactive T cells in the thymus. Transfer studies in mice revealed that AIRE 
expression in mTECs is crucial for negative selection of developing T-lymphocytes in 
the thymus and that AIRE mediate this by the expression of tissue specific antigens 
(TSAs) that are normally expressed in the periphery (Anderson et al., 2002).  
However, taking a major leap forward in the understanding of AIREs 
function, this story has a few flaws that may not fully explain the disease in APS I 
patients. For example, the same group also performed a study where they used a double 
transgenic mouse where ovalbumin was expressed in the thymus under the control of 
the rat insulin promoter and the T-lymphocytes only recognized a specific ovalbumin 
peptide. This study revealed that the negative selection of ovalbumin specific T-
lymphocytes was impaired in the Aire-/- mice, but the levels of ovalbumin in the thymus 
of these mice was not reduced (Anderson et al., 2005). Furthermore, others showed that 
the autoreactive T-lymphocytes in Aire-/- mice react to antigens that are not regulated 
by AIRE in the mTECs (Kuroda et al., 2005). Also, mice that lack Aire on a NOD 
background display severe exocrine pancreatitis, a manifestation that has never been 
found in APS I patients. These mice show no destruction of the β-cells in the pancreas 
although insulin is supposed to be differentially regulated by AIRE in the thymus 
(Jiang et al., 2005). Thus, the control of TSA expression by AIRE in mice does not 
seem to correlate with the peripheral autoantigens causing organ destruction in APS I 
patients and indicate that APS I may not only be caused by faulty negative selection of 
autoreactive lymphocytes by mTECs. These findings, together with data of AIRE 
expression in cells other than the mTECs has led to an emerging set of reports 
investigating the role of AIRE in peripheral organs.  
One study revealed that Aire-/- peripheral dendritic cells (DCs) show 
differential expression of several genes, including the co-stimulatory molecule VCAM-
1. The overexpression of VCAM-1 could be coupled to an increased ability of Aire-/- 
DCs to activate naïve T cells (Ramsey et al., 2006). Furthermore, Aire-/- mice also 
display a clear B cell phenotype, attributed by infiltrates of B cells in the liver and the 
development of marginal zone B cell lymphomas in aged mice (Hässler et al., 2006). 
The findings in Paper I reveal the mechanisms behind this phenotype of overactivated 
B cells that is unlikely to be caused by defective negative selection of autorective T 
cells in the thymus. In this paper it was demonstrated that increased activation of DCs 
in absence of AIRE affect the activation of B cells in a T-cell independent manner. 
Aire-/- mice injected with T cell-independent antigen TNP-Ficoll showed an increased 
response in vivo and an overall increased activation status, in particular of MZB cells. 
This increased activation was found to be caused by excessive release of BAFF 
cytokines mediating survival of B cells in both Aire-/- mice and APS I patients. 
Performing bone marrow transfer of Aire-/- bone marrow into T cell deficient nude mice 
revealed that the increased secretion of BAFF was independent on autoreactive T-
lymphocytes. Instead, the increased levels were caused by a continuous signaling of 
IFN-γ through the STAT1 pathway. This was hypothesized when a publication 
demonstrated that AIRE and PIAS1 interacted functionally to inhibit STAT1 signaling 
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(Ilmarinen et al., 2008), suggesting that in the absence of AIRE, STAT1 signaling is not 
inhibited and excess levels of IFN-γ targeted genes, as BAFF, is being transcribed. 
These findings together with the fact that AIRE is expressed in dendritic cells in the 
periphery lead to the investigations of Paper II.  
The localization of AIRE/AIRE expression has been widely debated over 
the years and the fact that no clear function of the role of AIRE in cells other than the 
mTECs has fueled the skeptics that AIRE has no role in peripheral tolerance. However, 
Aire/AIRE has been found to be expressed in a range of cells and tissues and the 
expression of AIRE in DCs would coincide with the cells function as a professional 
presenter of antigens and mediator of tolerance mechanisms. In Paper II, we 
investigated the subtypes of DCs in the spleen because of the previous findings of 
overactivated lymphocytes in this organ. Interestingly, we found AIRE expression in a 
subtype of DC that is situated in the marginal zone and red pulp areas of the spleen. 
This study demonstrated that this subset possess functions that can aid the processes of 
B and T-lymphocyte activation and germinal center selection. For example, the 33D1+ 
DCs express the co-stimulatory molecule ICOSL that was found to be regulated by 
AIRE and thus regulate the activation of T-follicular helper cells in germinal center 
reactions. It is tempting to speculate that the Aire regulation of 33D1+ DCs including 
higher expression of ICOSL in Aire-/- mice could add to the pathology also in APSI 
patients. Also, these DCs were found to express the hallmark TSA insulin in an AIRE 
dependent manner. Paper III further demonstrated that AIRE is connected to the 
STAT1 pathway not only by the inhibition of IFN-γ signaling but also that Aire/AIRE 
itself is regulated by IFN-γ. The down regulation of Aire in the 33D1+ DCs during IFN-
γ stimulation also lead to the down-regulation of insulin expression. This effect of IFN-
γ has also been demonstrated in mTECs in the thymus and strengthens the role of the 
33D1+ DC subset as a regulator of tolerance (Levi and Polychronakos, 2009). 
Furthermore, this finding also suggests that the 33D1+ DCs are able shift from a 
tolerogenic function in steady state to an immunogenic function during an immune 
response.  
In Paper IV the origin of the 33D1+ DCs with regard to Aire induction 
was investigated. This study revealed that Aire may influence the proper maturation of 
33D1+ DCs in the bone marrow. Further studies on the maturation of 33D1+ DCs in the 
bone marrow is needed in order to elucidate whether AIRE is really affecting this part 
of development.  
In summary, the findings of the work included in this thesis suggest that 
AIRE has a role in dendritic cell biology in the periphery, in particular in the subset of 
DCs in the marginal zone of the spleen. Although sharing some features with the 
mTECs, the marginal zone DCs seem to have some additional distinct functions that 
most probably have evolved from the fact that these cells are situated in the peripheral 
organs where the purpose of AIRE may be different. I hope that the work in this thesis 
help to move the focus from thymic AIRE in the medulla and further broaden the view 




3 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kroppens immunförsvar har utvecklats för att skydda oss mot mikroorganismer som 
farliga bakterier, virus och svamp. Vår hud och våra slemhinnor skyddar oss från en del 
av dessa angrepp men specialiserade immunceller i kroppens organ, så som mjälte och 
lymfkörtlar, behövs för att kroppen skall kunna stå emot specifikt argsinta och 
återkommande angrepp. Dessa celler är dendritceller som är specialiserade på att suga 
upp mikrober och skylta med dem för T och B-celler. T-celler utvecklas i tymus och är 
specialiserade på att eliminera farliga mikroorganismer och B-celler utvecklas i 
benmärgen och har som uppgift att producera antikroppar. Antikroppar fungerar som 
varningssignaler som mycket snabbt upplyser övriga celler om att en viss 
mikroorganism har tagit sig in i kroppen. Under sin utveckling i respektive organ 
genomgår T och B-cellerna flera selektioner som ser till att de reagerar på 
mikroorganismer som har tagit sig in i kroppen utifrån och att de inte reagerar på de 
celler och mikroorganismer som redan finns i kroppen naturligt. Celler som reagerar på 
kroppens egna mikroorganismer kommer att bli eliminerade för att förhindra att dessa 
tar sig runt i kroppen och förstör organ. Förmågan att kunna skilja på eget och 
främmande kallas tolerans. När selektionen av T och B-celler inte fungerar som den ska 
kan själv-reaktiva, eller autoreaktiva celler, ta sig runt i kroppen och leda till 
autoimmun sjukdom.  
Autoimmuna sjukdomar så som diabetes och multipel skleros blir allt 
vanligare. I nuläget finns inget botemedel för autoimmunitet men det går att behandla 
en del av de symptom som uppstår i samband med sjukdomen. I den här avhandlingen 
har jag studerat en gen som är viktig för att tolerans ska uppstå, AIRE (AutoImmune 
Regulator). Mutationer i denna gen leder till en svår autoimmun sjukdom som kallas 
APS I (Autoimmunt polyendokrint syndrom typ I). APS I är en monogen recessivt 
ärftlig sjukdom, vilket innebär att en individ vars föräldrar har en mutation i AIRE 
kommer att utveckla APS I med mycket stor sannolikhet. Patienter med APS I lider av 
flera symptom som kan bli livshotande om de inte kontrolleras och behandlas. De 
vanligaste förekommande symptomen kommer från skador på organ som producerar 
hormon, såsom bisköldkörteln, binjurarna och bukspottkörteln. Det är även mycket 
vanligt att patienterna drabbas av svåra kroniska svampinfektioner i munnen.  
Det är inte helt klargjort vilken roll AIRE har i utvecklingen av tolerans. För att kunna 
studera detta använder vi oss av möss som har en defekt AIRE gen liknande den 
mutation som patienter med APS I har. Med hjälp av dessa möss har forskare kommit 
fram till att AIRE är viktig för att autoreaktiva T-celler i tymus ska kunna elimineras. I 
avsaknad av AIRE cirkulerar autoreaktiva celler runt i immunsystemet och förstör 
kroppens celler och vävnad.  
I den första artikeln i den här avhandlingen visar vi att avsaknad av AIRE även leder till 
att B-celler blir överreaktiva och producerar ovanligt stora mängder av antikroppar. 
Detta tror vi beror på att dendrit-cellerna i de AIRE defekta mössen och i APS I 
patienterna producerar mycket höga nivåer av en faktor som aktiverar B-celler och 
kallas för BAFF. 
I den andra artikeln visar vi att AIRE finns i en specifik typ av dendritcell i mjälte och 
lymfkörtlar. Den här dendrit-cellen producerar, förutom BAFF, även andra faktorer 
som är viktiga för aktivering av T-celler och för att B-celler ska röra sig i mjälten. När 
AIRE inte uttrycks där bidrar dendritcellen till att aktiverade T och B-celler blir 
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överaktiverade i mjälten och får svårt att röra sig som de ska för att kunna vara med och 
hjälpa till under immunsvaret. 
I det tredje arbetet har vi studerat hur uttrycket av AIRE kan regleras i den specifika 
dendritcellen i mjälten. När dendritcellen stimuleras med en molekyl som kallas 
interferon-γ går uttrycket av AIRE ner. När AIRE går ner går även uttrycket av gener 
som är viktiga för tolerans ner. Interferon-γ utsöndras bland annat av T-celler för att 
varna om att till exempel ett virus har kommit in i kroppen. Våra data tyder på att denna 
dendritcell möjligen har olika uppgifter i kroppen som bidrar till tolerans i en frisk 
kropp, men kan även prioritera att verka i försvaret mot invaderande mikroorganismer 
under en infektion.      
I det fjärde arbetet undersöker vi hur dendritcellerna utvecklas i 
benmärgen utan AIRE och även om AIRE normalt uttrycks i tidiga dendritceller i 
benmärgen. Vi fann att AIRE uttrycks redan i ett förstadie till dendritcellen i mjälten 
och att när AIRE inte finns i benmärgen så saknas några av de gener som behövs för att 
dendritcellen ska fungera korrekt.   
Sammanfattningsvis så bidrar våra upptäcker till att öka förståelsen om 
hur AIRE är viktig för att skapa tolerans på flera sätt. Genom att studera hur AIRE 
fungerar hoppas vi kunna hjälpa till att förstå hur autoimmunitet uppstår och 
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